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Multidrug resistance (MDR) in cancer and other diseases is frequently associated with
transmembrane efflux proteins, one of which is P-glycoprotein (P-gp). Over-expression of P-gp
in cancer cells increases the efflux of therapeutic drugs rendering them ineffective. In order to resensitize multidrug resistant cancers to chemotherapy, we have found potential inhibitors of P-gp
by in silico screening methods, and several of these inhibitors were shown to successfully
overcome MDR in the drug resistant DU145TXR prostate cancer cell line. The best of the
identified hit compounds were further investigated with regard to the mechanism of inhibition
using ATPase activity assays and electron spin resonance spectroscopy (ESR). Using a spinlabeled ATP analog and ESR spectroscopy, we assessed the effects of the identified inhibitors on
ATP binding to P-gp. In the ATPase activity assays, it was found that the environment of P-gp is
extremely important for drug discovery efforts using purified membrane proteins.
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CHAPTER 1
INTRODUCTION

1.1 Multidrug resistance (MDR) in cancers and P-gp
Multidrug resistance (MDR) proteins protect normal cells from xenobiotic attack by
pumping a large range of toxins out of the cell. Unfortunately, over-expression of these proteins
in cancer cells increases efflux of therapeutic drugs rendering them ineffective [1]. MDR
proteins mainly consist of membrane proteins P-glycoprotein (P-gp), breast cancer resistance
protein (BCRP) and multidrug resistance-associated protein (MRP-1). P-gp and BCRP play a
functional role in blood brain barrier (BBB) to protect the brain from xenobiotics and toxins.
However, overexpression of these two transporters prevents chemotherapeutics from entering the
brain to treat cancers. P-gp is unique in a way that it has broad and diverse substrate spectrum
with few common chemical properties. This allows for the protection of normal cells from the
attack of toxins but in the meantime, it makes it harder for the selection of P-gp inhibitors or in
the search for chemotherapeutic drugs. Endogenous substrates of P-gp include lipids, small
peptides, steroid hormones, and small cytokines. In normal tissues, P-gp is expressed at a low
level throughout the body, but a high level in the secretory and excretory tissues. This tissue
distribution suggests a protective role of P-gp by preventing toxins or drugs entering our body.
Constant exposure of chemotherapeutics to cancer cells induces the increase of P-gp expression
in recurrent cancers as compared to the initial diagnosis [2-4]. Advanced cancers with high P-gp
expression are generally unresponsive to chemotherapeutics that are substrates of P-gp [5-7].
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P-gp has been known as a major cause of multidrug resistances in cancers for over 35
years. P-gp hydrolyzes ATP to catalyze the transport of hydrophobic drugs across the plasma
membrane and out of cells. Frequent exposure of cancer cells to drugs induces over-expression
of P-gp resulting in populations of cancer cells that are resistant to chemotherapeutics [1, 8, 9],
although MDR can be caused by a number of different mechanisms [10]. P-gp is expressed as a
single polypeptide that has 1280 residues with two nucleotide binding domains (NBDs) and two
transmembrane domains (TMDs)/drug binding domains (DBDs). Each transmembrane domain
has six helices where substrates and drugs bind. Several crystal structures of P-gp homologs
from bacteria, C. elegans and mouse have been reported [11-15]. The two halves of P-pg are
connected by a flexible linker polypeptide, which plays a crucial role in bringing two NBDs
together to form ATP binding sites.
1.2 Generation of P-gp inhibitors
Due to the trend that patients with MDR cancers have a high expression of P-gp,
inhibition of P-gp by modulators in MDR cancers may play a crucial role in sensitizing the
cancer cells to chemotherapeutics and thus reversing MDR. Since the report of verapamil, a
transport substrate of P-gp, to reverse MDR by Tsuruo et al[16-18], the search for P-gp
inhibitors, mostly small, drug-like molecules, has drawn wide attention and is still on-going until
now. In general, there are three generations of small molecules that are classified as P-gp
inhibitors.
First generation P-gp inhibitors consist of already approved drugs for other indications
that were shown to increase the cytotoxicity of chemotherapeutics in MDR cancer cells. These
pre-approved drugs include verapamil (calcium channel blocker), cyclosporin A
(immunosuppressant), propafenone, quinidine, quinine, and niguldipine and nifedipine (calcium
2

channel blockers). These inhibitors were found to be substrates of P-gp and they sensitized MDR
cancer cells by competing with chemotherapeutics for transport thus preventing them from being
pumped out of cancer cells [16, 19]. In other words, they restored the chemosensitivity by
increasing the accumulation of chemotherapeutics inside cells. In order to achieve high
cytotoxicity of cancer cells, high concentrations were required which resulted in unacceptable
side effects[20, 21].
Second generation P-gp inhibitors are like the first generation but with high affinities to
P-gp and minimized negative pharmacological properties. These inhibitors are more effective,
but many of them are P-gp substrates that require high concentrations. They largely failed in
clinical trials due to low efficacy and high toxicities. Some also affected other enzymes such as
the cytochrome P450 drug metabolizing enzyme, altering the pharmacokinetics of other
drugs[10, 22].
Third generation P-gp inhibitors aim to find more specific and highly potent small druglike molecules taking advantage of combinatorial chemistry and quantitative structure-activity
relationships (QSAR)[23]. This generation includes several highly potent compounds such as
tariquidar, zosuquidar, laniquidar, elacridar and biricodar[24-26]. These drugs are largely not
known to be substrates of P-gp. Tariquidar was suggested to bind to the nucleotide binding
domains (NBD) or an allosteric location of P-gp[27, 28]. Although these were designed to be
specific P-gp inhibitors, it was reported that some actually interacted with other ABC
transporters[28, 29]. The ongoing clinical trials had limited success and up to now there is no Pgp inhibitor approved for use.
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1.3 P-gp dynamics
Several crystal structures of P-gp homologs from bacteria, C. elegans and mouse have
been reported [11-15]. The derived mouse P-gp crystal structure had an inward-facing
conformation with two NBDs disengaged without ATP bound [30]. A bacterial ABC transporter,
Sav1866, from Staphylococcus aureus revealed outward-facing conformations with ADP bound
[12] or AMP-PNP protein bound [13]. In the structure with nucleotides bound, the two NBDs
were in close contact and the two transmembrane domains (TMDs) adopted an outward-facing
open conformation. The nucleotide-free conformation revealed dissociated NBDs. The
nucleotide-bound structure changed the accessibility of the transporter from inward facing to
outward facing [14]. In previous studies, we reported conformational transitions of human P-gp
in a catalytic cycle based on these existing crystal structures of P-gp homologs using in silico
molecular dynamic and targeted molecular dynamics techniques. Twenty six transitional
structures of P-gp were produced from wide open to the cytoplasm to wide open to the
extracellular space [31]. Besides our predictions from computational simulations, several models
have been proposed by analysis of biochemical and biophysical studies of the catalytic and
transport cycle of P-gp and other ABC transporters [12-14, 32, 33]. Controversy exists with
regard to dependence of conformational transition of TMDs upon ATP binding and/or
hydrolysis.
Upon substrates binding to the TMD of P-gp, both the NBD and TMD domains appear to
undergo significant conformational changes during the catalytic cycle[34-37]. In the absence of
ATP, the TMD is open to the inside of the cell with the NBDs disengaged and sometimes fully
separated [11, 14, 38]. When ATP is bound to the NBDs, some structural models show fully
engaged NBDs with one nucleotide on each side and widely open TMDs to the outside of the
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cell. Based on several crystal structures of homologs in various conformations, targeted
molecular dynamics of human P-gp simulated the dramatic conformational changes during a
catalytic cycle [31]. Upon substrate binding to the drug binding domains (DBD) of the fully
inward opening P-gp, the ATP binding affinity to the NBD is increased. When two ATP bind to
the NBDs, the NBDs engages and induces a significant conformational change in the DBDs from
fully inward opening to partially inward opening, partially outward opening and fully outward
opening at the end of the conformational changes. The fully outward opening reduces the
substrate binding affinity, so it is released [31].
We have recently created computational models of the human P-glycoprotein [31] and
have used these models to perform ultrahigh throughput screens to identify novel inhibitors of
the pump to counteract multidrug resistances. To further investigate the mechanism underlying
the inhibition, we have employed biochemical assays and electron spin resonance spectroscopy
(ESR), and have established nanodisc technologies that provide a native-like phospholipid
bilayer environment to incorporate and stabilize P-gp for our drug finding and mechanistic
studies.
1.4 Inhibitor screening of P-gp
Using in silico screening approaches, we have identified a few compounds, such as
SMU19, 29, 34 and 45 that inhibited P-gp enzymatic activity [39]. Among them, SMU29, 34 and
45 sensitized MDR resistant prostate cancer cell line DU145TXR [40] to chemotherapeutics.
SMU19 failed in this in vitro test because of its negative charge that prevented it from entering
cells. SMU29 did not inhibit ATP binding in biophysical studies, indicating it potentially bound
to an allosteric site on P-gp, while others inhibited ATP binding, indicating they bound to the
DBDs or to allosteric sites that affected ATP binding. These compounds only had minimal
5

cytotoxicity toward normal cells such as HFL1 non-cancerous cells [41]. Inspection of the in
silico docking site of SMU29 to the allosteric site of P-gp revealed considerable space that could
allow more interaction between protein and ligand. In an effort to improve the binding affinity of
SMU29 to P-gp by introducing additional interactions, a novel computer-aided and structurebased approach was employed to optimize SMU29 [31]. All these variants of SMU29 were
assessed for their reversal of MDR in DU145TXR, and their inhibition of pumping of a P-gp
substrate. Furthermore, these variants were tested in the biochemical and biophysical assays to
investigate their inhibition mode of ATP hydrolysis and ATP binding.
Several other in silico identified compounds, SMU50 to 98, were also tested with this cell
line, and several of them successfully reversed its MDR [42]. We also performed biochemical
assays to identify P-gp enzymatic inhibitors from SMU50 to 98, and several of them showed
significant inhibition especially in the presence of P-gp substrate verapamil in the stimulated
activity assay. Compounds from SMU50 to 98 that successfully inhibited P-gp activity in vitro
and reversed multidrug resistance in MDR DU145TXR cells were subjected to biophysical
assays to investigate mechanisms underlying the inhibition. More specifically, we investigated
whether our compounds inhibited ATP binding to the nucleotide binding domain or to an
allosteric site that hindered the conformational changes of P-gp during the catalytic cycle. A new
group of compounds SMU99 to 124 were computationally identified and purchased from
commercial sources (McCormick, et al., unpublished). They were also screened using MDR
DU145TXR cell line and purified P-gp in biochemical and biophysical assays.
1.5 Inhibitor binding to P-gp
Electron spin resonance spectroscopy, ESR or EPR, has been used successfully over the
last several years to study structural and conformational changes of many different membrane
6

proteins, for examples see [43, 44]. In contrast to the more frequently used NMR spectroscopy,
ESR relies on the occurrence of unpaired electrons that are excited in the course of the
experiment. Due to the lack of naturally occurring unpaired electrons in biological systems, the
technique often relies on introduction of stable organic radicals, spin labels, into regions of
interest within the studied protein. The procedure is referred to as “site-directed spin labeling”
and is a combination of site-directed introduction of cysteine amino acid residues and subsequent
chemical modification with cysteine-reactive spin labels [44]. In addition to providing general
information about the relative environment of the introduced spin label, the technique also allows
for the measurement of inter-spin distances of two or more spin labels at close spatial vicinity.
Inter-spin distances of up to 25 Å can be assessed using X-band ESR spectroscopy, which has
been successfully employed by others and in our group [45-47]. Distances larger than 25 Å can
be measured using pulsed ESR techniques [48, 49].
One additional application for ESR spectroscopy is its ability to study nucleotide binding
to a protein using spin-labeled nucleotide analogs. Our group has used this technique to study a
wide variety of ATP binding proteins, including ABC transporters [50, 51]. Using a spin-labeled
ATP derivative, SL-ATP [52], our group was able to determine for the first time nucleotide
binding affinity and maximum binding to P-gp and the multidrug resistance associated protein,
MRP3, under equilibrium conditions. This was made possible by the fact that the ESR signal of
protein-bound SL-nucleotide is sufficiently different from free, unbound ligand so that both
states could be observed simultaneously. Since earlier experiments showed that SL-ATP was
hydrolyzed by P-gp [51], the phosphorylation state of the nucleotide was unknown. SL-ATP that
had been incubated with P-gp for any amount of time is therefore referred to as SL-ANP, where
ANP refers to an unknown number of phosphates attached to the adenosine moiety.
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One draw-back of using ESR spectroscopy to study proteins is that it requires relatively
high concentrations of proteins for good signal to noise ratios. At a minimum, 30 micromolar of
spin label is needed for appropriate ESR signal. Especially when studying membrane proteins,
these relatively high concentrations of protein are often hard to achieve. In previous work, our
group has purified P-glycoprotein and other ABC transporters into mixed micelles that can be
concentrated to the appropriate needed concentrations [39, 50, 51].
1.6 Reconstitution of P-gp into nanodiscs
In recent studies we have utilized computational models [31, 39, 53] to identify small
drug-like compounds that reverse P-glycoprotein-mediated multidrug resistance in cancer cell
lines [42]. Before these compounds can be used in pharmaceutical industry, the mechanism of
their inhibition of P-gp needs to be investigated. For the development of drugs that are targeting
soluble proteins, co-crystallization of proteins with the respective drugs is often a pre-requisite.
For membrane proteins like P-gp, X-ray crystallography often is problematic, thereby making
drug development more problematic. Fully validated computational models for such difficult to
crystallize drug targets may therefore be the next best alternative to more rigorous structural
studies. We used biochemical assays and ESR spectroscopy to validate the computational models
with biochemical and biophysical data and to evaluate the mode with which potential inhibitors
interact with the target protein. To increase the stability of the P-gp mutants for biochemical and
biophysical analyses, P-gp mutants reconstituted into membrane nanodiscs as described in [54]
were used. Traditionally, membrane proteins are solubilized in detergents to form mixed
detergent-protein-lipid micelles. However, micelles pose problems to membrane protein stability
and can cause undesired partitioning of substrates into them [55]. In addition, many membrane
proteins require specific lipids to maintain their activity and detergents are not able to meet this
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requirement. Liposomes have been widely used to study membrane protein. However, liposomes
are difficult to prepare with a homogenous size. Additionally, the directionality of protein
insertion into liposomes may be problematic as it may shield important parts of the protein from
the soluble phase of the experiment. Nanodisc technology therefore provides a solution to many
of these problems and may offer advantages over micelles and liposomes in terms of activity,
stability and size. We optimized the reconstitution of human P-glycoprotein into nanodiscs. Due
to the fact that the currently available clones for human P-gp express the protein in only
relatively small amounts, we optimized the procedure for nanodisc reconstitution using a mouse
homologous P-gp that can be expressed at a higher yield in our lab (~50 mg/L).
P-glycoprotein has proven to be hard to study [50, 51] using ESR. A solution to this
problem also came with the discovery of membrane nanodiscs by the Sligar group [55-57]. A
nanodisc is a patch of phospholipid bilayer encircled by two membrane scaffold proteins (MSP),
modeled after the serum apoprotein A-1. The hydrophobic side of the MSP is in direct contact
with the lipid bilayer, and the hydrophilic surface is exposed to water. Therefore, membrane
proteins incorporated into nanodiscs are soluble in aqueous solutions in the absence of detergents
[55-57]. Typically, the average diameter of nanodiscs ranges from 9.5 to 12.8 nm depending on
the length of MSP surrounding the lipid part of a nanodisc [55]. A typical thickness of a lipid
bilayer in nanodiscs of different sizes was confirmed to be 5.5 nm. Figure 1 shows an empty
nanodisc [58]. Membrane proteins incorporated into nanodiscs are typically more active and
stable than those solubilized in detergents and may represent more native-like structures. We
used nanodiscs to study the binding characteristics of SL-ATP to P-glycoprotein using ESR
spectroscopy. We furthermore used nanodisc incorporated P-gp to screen for inhibitors of the
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pump in biochemical assays and to assess the mechanism of inhibition of in silico predicted P-gp
inhibitors.

Figure 1 Structure of empty nanodiscs.
Top panel: top view; bottom panel: side view. Lipid bilayer (white fillings) is encircled by two
membrane scaffold proteins (MSPs, gray ribbons) [58].
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CHAPTER 2
RESULTS COMPOUNDS 99-124

2.1 Screening in silico discovered potential P-glycoprotein inhibitors for paclitaxel
sensitization of a paclitaxel-resistant prostate cancer cell line, DU145TXR
In silico docking experiments, similar to [59], were done to expand our search for P-gp
inhibitors (McCormick, unpublished) from compound 99 to 124, labeled by numbers by their
arrival in our lab. Compound 11-98 were screened using P-gp overexpressing prostate cancer
cell line , DU145TXR (TXR) [40]. Similarly in this work, DU145TXR (TXR) was also used to
screen these newly in silico identified potential P-gp inhibitors. TXR cells were incubated with
the compounds in the presence of the chemotherapeutic drug, paclitaxel (PTX), in order to test
the sensitization of TXR cells to paclitaxel by these compounds. In other words, this test was to
find potential inhibitors of P-gp that were able to reverse the resistance of TXR cells to PTX.
PTX alone does not inhibit the growth of TXR cells at 500 nM. However, in combination with
13 out of the 26 novel compounds at 10µM, PTX at 500nM dramatically inhibited the growth of
TXR cells by at least 48% as observed in resazurin assays [60] (see dark grey bars in the top
panel of Figure 2). We also tested the toxicity of these compounds themselves to the TXR cells.
The rationale was that if compounds were toxic to TXR cells they might also be harmful to
normal cells in our body, which should be avoided. So, we aimed to find compounds that
displayed the least toxicity themselves but were effective in enabling PTX to kill the TXR cells.
As shown as the light grey bar in the top panel of Figure 2, in the absence of paclitaxel, 21 out of
26 compounds showed inhibition of the growth of TXR cells by less than 20%.
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We then tested compounds that showed more than 48% inhibition in combination with
PTX at a lower concentration (2.5µM) of the experimental compounds. The rationale was that
compounds such as 102, 103 and 104 that showed inhibition in combination with PTX at 10µM,
but that were also toxic to TXR cells by themselves at this concentration, may be effective at
reversing PTX resistance but be less toxic at lower concentrations. The bottom panel in Figure 2
shows the results of these experiments. Compounds 102 and 103 did not show much toxicity at
2.5µM, but they still caused inhibition of cell viability when in combination with PTX.
Compound 104 lost its inhibition effect at 2.5µM although its toxicity was not observed at this
concentration as well. Ten more compounds, 101, 108, 109, 111, 112, 117, 119, 120, 122 and
123 that showed high levels of inhibitions and low toxicities were also tested at 2.5µM.
Compounds 108 and 117 maintained the reversal of MDR at 2.5µM while they showed minimal
toxicity, similar to that at 10µM. From these experiments, we were able to identify 4 compounds,
102, 103, 108 and 117 that met our requirements of high reversal of MDR and low toxicity as
observed in resazurin viability assays. These four compounds were further explored in additional
assays. In the experiments described here, the P-gp substrate and competitive transport inhibitor,
verapamil [61] was used as a control at the same concentration as the experimental compounds,
similar to experiments in [4]. The potent P-gp inhibitor, tariquidar [26] [62], was used as another
positive control at 500nM. The residual viability of TXR cells treated with compounds alone at
10µM and 2.5µM or in combination of 500nM PTX is summarized in Table 1.
In Table 1, “Δ” represents the viability difference between cells treated with compounds
alone and in combination with 500nM PTX. “NA” means no data is available, because the
compounds had shown less than 48% inhibition in the presence of experimental compounds and
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500 nM PTX. Data represent the mean (n≥6) of at least two independent experiments ± standard
deviation. Compounds that were selected to be tested at 2.5 µM are indicated in bold in Table 1.
These compounds at 10 µM inhibited cell viability by more than 43% in the presence as
compared to the absence of 500 nM PTX, except for compounds 102, 103 and 104, which have
much lower Δ values and are indicated in red. However, compounds 102 and 103 have Δ values
of more than 42% at 2.5 µM in the presence of PTX. Compounds with Δ values at 2.5µM that
are > 42% are in bold in the very right column in Table 1.
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Viability (% of DMSO)

99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
verapamil
tariquidar

viability (% of DMSO)

120%
100%
80%
60%
40%
20%
0%

100%
50%
0%

Figure 2 Screening in silico discovered potential P-gp inhibitors for paclitaxel sensitization of a
paclitaxel resistant prostate cancer cell line DU145TXR.
Screening in silico discovered potential P-gp inhibitors for paclitaxel sensitization of a paclitaxel
resistant prostate cancer cell line DU145TXR. DU145TXR cells were incubated with 10µM (top
figure) or 2.5µM (bottom figure) experimental compounds alone (light grey) or in combination
with 500nM paclitaxel (dark grey) for 48h, and the viability was determined using the resazurin
assay. Verapamil concentrations were the same as compounds. The concentration of tariquidar
was 500nM.
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Compound
No.

Compound
(10µM)
only

Compound
(10µM) +
PTX

Compound
(2.5µM)
only

Compound
(2.5µM) +
PTX

Δ[Compound
(10µM) ±
PTX]

Δ[Compound
(2.5µM) ±
PTX]

99

76±4

64±1

NA

NA

12

NA

100

99±1

81±5

NA

NA

18

NA

101

83±7

36±1

97±13

73±2

47

24

102

48±6

36±3

88±12

46±2

12

42

103

64±3

34±1

83±10

39±2

30

44

104

55±4

40±3

108±2

94±3

15

14

105

99±1

56±1

NA

NA

43

NA

106

101±0

64±3

NA

NA

37

NA

107

88±5

74±9

NA

NA

14

NA

108

86±13

26±1

100±2

46±1

60

54

109

94±6

31±3

89±10

71±5

63

18

110

96±2

82±8

NA

NA

14

NA

111

99±1

37±1

108±3

81±7

62

27

112

88±1

35±1

95±3

69±3

53

26

113

104±1

91±2

NA

NA

13

NA

114

93±9

67±5

NA

NA

26

NA

115

85±4

62±9

NA

NA

23

NA

116

77±1

55±4

NA

NA

22

NA

15

117

95±3

22±2

100±3

29±1

73

71

118

97±10

83±2

NA

NA

14

NA

119

91±2

48±2

113±10

112±3

43

1

120

99±1

37±1

109±0

94±2

62

15

121

107±1

57±3

NA

NA

50

NA

122

103±5

52±3

110±1

90±2

51

20

123

103±4

34±8

90±14

77±4

69

13

124

119±1

71±9

NA

NA

48

NA

VPL

101±2

21±1

93±12

18±1

80

75

TQR

99±1

21±2

NA

NA

78

NA

Table 1 Effects of experimental compounds on paclitaxel toxicity to DU145TXR cells line
culture.
The cell viability results from Figure 2 are represented as numerical values that were normalized
to DMSO vehicle controls. The 1st lane represents the compound number and lane 2-5 represents
% viability of cells treated with compounds alone at 10 or 2.5µM or in combination with 500nM
PTX. In lane 6 and 7, Δ represents the viability difference between cells treated with
experimental compounds or P-gp inhibitors alone and in combination with 500nM PTX. NA
means no data is available for compounds.
2.2 Predicted P-gp inhibitors reverse paclitaxel resistance in paclitaxel-resistant prostate
cancer, DU145TXR, cells
In order to determine the effects of the experimental compounds on the IC50 values of
PTX in the DU145TXR cell line, different concentrations of PTX were included in resazurin
assays [60] with or without 2.5 µM compounds (Figure 3). Two compounds that were identified
as P-gp inhibitors previously, compounds 29 [4, 7, 10] and 31(unpublished), were also included
in this experiment as comparison to see whether the newly discovered compounds would have a
better performance in inhibiting TXR cells or if they would require less PTX to achieve the same
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level of inhibition of TXR cells. Again, tariquidar was used a positive control and DMSO was
used as vehicle-only control at the same concentrations of PTX. Each compound is represented
using defined symbols and colors for data points and their fitted curves, respectively. DMSO
treated cells without PTX or compounds was set as 100% viability. From the fitted curve for
each compound, the PTX IC50 in the presence or absence of the experimental compounds was
derived using nonlinear, four-parameter logistic analysis with GraphPad Prism 8.0.2, which was
also used for all curve fittings in the later experiments unless otherwise stated. The PTX IC50 in
nM in the presence of all compounds tested are summarized in Table 2.

Figure 3 In silico identified potential P-gp inhibitors reverse paclitaxel resistance of DU145TXR
cells.
TXR cells were incubated with a range of paclitaxel concentrations in combination with 2.5µM
of compounds 101, 102, 103, 108, 109, 117, tariquidar, 29 and 31. “C number” means compound
number. After 48 hours, cell viability was determined by the resazurin assays. Data represents
the mean (n≥6) of at least two independent experiments with standard deviation error bars for
each data point shown above. Each compound is represented using defined symbols and colors
as above for data points and curves, respectively. The control is vehicle DMSO treated in the
presence of PTX without further additions of experimental compounds. For some data points, the
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error bars were smaller than the size of their symbols so they are not visible. Non-linear
regression was performed as described in Methods.

Compound

PTX IC50 (nM) in the
presence of Compounds
(2.5µM)

DMSO/no compound

3083±39

101

1027±51

102

268±11

103

239±14

108

412±12

109

929±11

117

89±4

TQR

NA

29

1093±53

31

128±12

Table 2 IC50 values of PTX on DU145TXR cells in the presence of experimental compounds or
P-gp inhibitors.
The PTX IC50 values for each compound were derived from the curve fitting of the plotted mean
viability presented in Figure 3. using nonlinear, four-parameter logistic analysis. Data represents
the mean (n≥6) of at least two independent experiments ± standard deviation. The unit of IC50 is
nM. DMSO means PTX only and no compound addition.
The experiment resulted in the discovery of four top hit compounds 102, 103, 108 and
117, which resulted in PTX IC50 values that were lower than those achieved in the presence of
compounds 101 and 109. This finding is consistent with the relatively low performance of 101
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and 109 at 2.5µM concentration. However, all of these novel compounds resulted in significantly
lower PTX IC50 values than that observed in the DMSO/PTX only treated cells. Compound 29
resulted in a similar PTX IC50 value as compounds 101. Compound 31 resulted in the second
lowest PTX IC50 value and 117 resulted in the lowest of 89 nM as shown in Table 2. The data
indicate that our novel compounds reversed the multidrug resistance of TXR cells at 2.5µM to
achieve PTX IC50 values in the sub-micromolar or nanomolar range.
2.3 Experimental compounds potentiate paclitaxel cytotoxicity in DU145TXR cell line
In order to assess the efficacy of the discovered hit compounds to potentiate the
cytotoxicity of paclitaxel to the P-glycoprotein overexpressing prostate cancer cell line,
DU145TXR, we performed resazurin cell viability assays [63] using a variety of concentrations
of compounds 102, 108 and 117 in assays similar to [63, 64] and in the presence of 500nM PTX
(Figure 4). Compounds 102, 108 and 117 were selected in this assay because they sensitized
PTX cytotoxicity at 2.5µM. Compound 29 was included to compare the previously identified
compound to the novel compounds. Verapamil was added as a control for P-gp inhibition. Each
compound is represented using defined symbols and colors for data points and their fitted curves,
respectively. The data were normalized to DMSO treated cells in the absence of PTX or
compounds and set as 100% cell viability. From the fitted curve for each compound, compound
PC50 was derived using nonlinear, four-parameter logistic analysis with GraphPad Prism 8.0.2.
The compound PC50 in µM for all compounds are summarized in Table 3. Compound PC50 was
defined as the concentration of compound that inhibited the viability of cancer cells by 50% in
the presence of 500 nM PTX.
Compound 117, one of the three novel compounds, showed the lowest PC50 value,
indicating that in the presence of 500nM paclitaxel it required the lowest concentration among
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the four experimental compounds to inhibit 50% viability of TXR cells. In other words, given the
same concentration of paclitaxel, 117 is the most effective probably due to its highest binding
affinity to P-gp than other compounds. So, when a fixed concentration of 2.5µM experimental
compounds was used for the sensitization assay as shown in Figure 3. and Table 2, in the
presence of compound 117 the least concentration of paclitaxel was required to achieve 50%
viability. In other words, at 2.5µM compound 117 inhibits the P-gp the most resulting that it
requires the least paclitaxel to inhibit 50% viability (IC50). Not surprisingly, compound 102 has a
lower PC50 value than 108 in the presence of 500nM paclitaxel, which resulted in a lower
paclitaxel IC50 value in the presence of 2.5µM compound 102 than 108. Furthermore, the highest
PC50 and IC50 values were observed for compound 29 in the presence of 500nM paclitaxel and
for paclitaxel in the presence of 2.5µM compound 29, respectively, as shown in Table 2 and
Table 3. In summary, the newly discovered compounds, 102, 103 and 117, were able to reverse
paclitaxel resistance in TXR cell line and potentiate paclitaxel cytotoxicity to TXR cells and
outperformed the previously discovered compound 29.
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Figure 4 Experimental compounds potentiate paclitaxel cytotoxicity in DU145TXR cell line.
TXR cells were incubated with a range of concentrations of experimental compounds 29, 102,
108, 117, and verapamil in combination with 500nM PTX. After 48 hours, cell viability was
determined using the resazurin assay. “C number” means compound number. Data represents the
mean (n≥6) of at least two independent experiments with standard deviation error bars for each
data point shown above. Each compound is represented using defined symbols and colors as
above for data points and curves, respectively. The data was normalized to DMSO treated cells
as 100% viability. For some data points, the error bars were smaller than the size of their
symbols.
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Compounds

Compounds PC50 (µM)

102

3.3±0.1

108

4.0±0.1

117

1.9±0.1

29

5.3±0.1

VPL

1.3±0.0

Table 3 Compounds potentiate paclitaxel cytotoxicity in DU145TXR cell line.
The compound PC50 value for each compound was derived from its curve fitting from the plotted
mean viability presented in Figure 4. using nonlinear, four-parameter logistic analysis as
describe in Methods. Data represents the mean (n≥6) of at least two independent experiments ±
standard deviation. VPL: verapamil.
2.4 Novel experimental compounds cause cellular accumulation of the P-gp substrate,
calcein-AM
In order to determine whether the increased paclitaxel toxicity to the P-gp overexpressing
DU145TXR cells was the result of increased cellular accumulation of a P-gp substrate due to Pgp inhibition, we assessed the accumulation of the P-gp substrate, calcein-AM in the cells treated
with the potential inhibitory compounds in experiments similar to those describe in[64]. CalceinAM becomes fluorescent upon entering the cells followed by esterolysis by cellular esterases and
is then no longer a substrate of the pump, resulting in accumulation of the fluorescent calcein [4].
Using this assay, we were able to record the amount of fluorescence intensity of calcein inside
cells in case the experimental compounds caused calcein accumulation by blocking P-
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glycoprotein action. The top four compounds 102, 103, 108 and 117 were investigated along
with the two previously identified compounds 29 and 31. Verapamil was used as a control that
inhibited P-gp by directly competing with calcein-AM transport. DU145TXR cells and the not Pgp overexpressing parental DU145 cells were used to compare P-gp substrate accumulation in
the absence of our compounds. Since TXR cells have significantly higher P-gp expression than
DU145, we hypothesized that they would accumulate calcein-AM to a much lower extend than
DU145 cells, similar to observations made in [4]. In the presence of the four top hits described
earlier, the accumulation of calcein as measured by relative fluorescence units (RFU) over time.
This resulting fluorescence accumulation curves should fall between the two curves representing
DU145 treated with DMSO vehicle only as 100% and TXR treated with DMSO only as 0%
(Figure 5B).
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A

B
Figure 5 Time dependent calcein accumulation in paired prostate cancer cell lines (DU145 &
DU145TXR).
DU145TXR cell line was incubated with 2µM calcein-AM for 40 minutes with or without
1.5µM P-gp inhibitory compound 102, 103, 108, 117, 29, 31 and verapamil. DU145 cell line was
incubated with 2µM calcein-AM for 40 minutes with DMSO only. A. Calcein fluorescent
intensity (RFU) was measured every 10 minutes. Data represents the mean (n≥6) of at least two
independent experiments with standard deviation error bars for each data point shown above.
Each compound was represented using defined symbols and colors as above for data points and
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curves, respectively. For some data points, the error bars are smaller than the size of their
symbols so they are not visible. B. P-gp efflux inhibition was calculated using equation % Efflux
Inhibition = (RFU slopecompound - slope TXR) / (slopeDU145 - slopeTXR) x 100. It represents the mean
(n≥6) of at least two independent experiments with standard deviation error bars. The calculated
% efflux inhibition is 100 for DU145/DMSO and 0 for TXR/DMSO (not visible). The slope for
each curve was acquired from the linear regression. Corresponding values were presented in
Table 4.
Figure 5A. shows that indeed in the presence of all of our best experimental compounds
the accumulation of calcein-AM in TXR cells was less than that of DU145 cells but higher than
that of TXR cells. TXR cells treated with compound 117 caused the most accumulation and
fluorescence levels closest to DU145 cells (as 100%), indicating that among all compounds
tested, 117 inhibited the P-gp the most. Below compound 117 were compounds 102 and 103
(overlapped) which showed similar effectiveness in blocking P-gp and causing calcein AM
accumulation while compound 108 seemed the least effective below the compound 29 curve.
Compound 31, one of the previously identified compounds, caused the least accumulation of
calcein, which was between compound 108 and TXR/DMSO. Although verapamil is a substrate
of P-gp used as a control here, it outperformed compounds 29, 31 and 108 but still was not as
good as our three top hits 102, 103 and 117.
Based on the accumulation of calcein by each compound, it is of interest to calculate the
inhibition of P-gp efflux by compounds that caused the accumulation. The calculated % efflux
inhibition is 100% for DU145/DMSO and 0% for TXR/DMSO (not visible). The reason we used
DU145/DMSO as 100% inhibition was it had the least amount of active P-gp present as
compared to TXR treated with any compounds in any of our tests. On the other hand,
TXR/DMSO was used as 0% inhibition because it had the most active P-gp in our tests. P-gp
efflux inhibition was calculated using equation % Efflux Inhibition = (RFU slopecompound - slope
TXR)

/ (slopeDU145 - slopeTXR) x 100. It represents the mean (n≥6) of at least two independent
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experiments with standard deviation error bars. The slope for each curve was acquired using the
linear regression. Corresponding values are presented in Table 4.
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A

B

Figure 6 Time dependent calcein accumulation in paired prostate cancer cell lines (DU145 and
DU145TXR) in the presence of 1.5 µM experimental compounds.
DU145TXR cell line was incubated with 2µM calcein-AM for 40 minutes with or without
1.5µM experimental P-gp inhibitory compounds 102, 103, 108, 117, 29, 31 and verapamil.
DU145 cell line was incubated with 2µM calcein-AM for 40 minutes with DMSO only. A.
Calcein fluorescent intensity (RFU) was measured every 10 minutes. Data represents the mean
(n≥6) of at least two independent experiments with standard deviation error bars for each data
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point shown above. Each compound is represented using defined symbols and colors as above
for data points and curves, respectively. For some data points, the error bars are smaller than the
size of their symbols so they are not visible. B. P-gp efflux inhibition was calculated using
equation % Efflux Inhibition = (RFU slopecompound - slope TXR) / (slopeDU145 - slopeTXR) x 100. It
represents the mean (n≥6) of at least two independent experiments with standard deviation error
bars. The calculated % efflux inhibition is 100% for DU145/DMSO and 0% for TXR/DMSO
(not visible). The slope for each curve was acquired using the linear regression. Corresponding
values are presented in Table 4.

Cell Line Treated
with Compounds
(1.5µM)

RFU/min

DU145/DMSO

10688±436

100±4

TXR/102

8002±200

73±2

TXR/103

7865±232

71±2

TXR/108

1476±18

5±0

TXR/117

9668±339

90±3

TXR/29

2934±34

20±0

TXR/31

1456±14

5±0

TXR/VPL

6720±208

59±2

TXR/DMSO

971±15

0±0

(RFU slope)

% Efflux
Inhibition

Table 4 Quantitation of P-gp efflux inhibition by experimental compounds at 1.5 µM in TXR
cells indicated by the accumulation of calcein-AM.
DU145TXR cell line was incubated with 2µM calcein-AM for 40 minutes with or without
1.5µM P-gp inhibitory compounds 102, 103, 108, 117, 29, 31 and verapamil. DU145 cell line
was incubated with 2µM calcein-AM for 40 minutes with DMSO only. The slope for each curve
from Figure 5A with standard deviation was acquired from the linear regression. P-gp efflux
inhibition was calculated using equation % Efflux Inhibition = (RFU slopecompound - slope TXR) /
(slopeDU145 - slopeTXR) x 100. It represents the mean (n≥6) of at least two independent
experiments ± standard deviation.
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Eq. 1. % Efflux Inhibition = (RFU slope compound - slope TXR) / (slope DU145-slope TXR) x 100
As shown in Figure 5., several compounds including compounds 102, 103 and 117 at
1.5µM caused significant accumulation of calcein, so it seemed of interest to test these
compounds at an even lower concentration, such as at 0.75µM, to see if they are still as effective.
The result was shown in Figure 6.
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A

B

Figure 7 Time dependent calcein accumulation in paired prostate cancer cell lines (DU145 &
DU145TXR) in the presence of 0.75 µM compounds.
DU145TXR cell line was incubated with 2 µM calcein-AM for 45 minutes with or without 0.75
µM P-gp inhibitory compounds 102, 103, 117, 29, and verapamil. DU145 cell line was incubated
with 2µM calcein-AM for 45 minutes with DMSO only. A. Calcein fluorescent intensity (RFU)
was measured every 10 minutes. Data represents the mean (n≥6) of at least two independent
experiments with standard deviation error bars for each data point shown above. Each compound
is represented using defined symbols and colors as above for data points and curves,
respectively. For some data points, the error bars are smaller than the size of their symbols so
they are not visible. B. P-gp efflux inhibition was calculated using equation % Efflux Inhibition
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= (RFU slopecompound - slope TXR) / (slopeDU145 - slopeTXR) x 100. It represents the mean (n≥6) of
at least two independent experiments with standard deviation error bars. The calculated % efflux
inhibition is 100% for DU145/DMSO and 0% for TXR/DMSO (not visible). The slope for each
curve was acquired using the linear regression. Corresponding values are summarized in Table
5.
As compared to Figure 6 using 1.5μM compounds, the efflux inhibition with 0.75μM
compounds drops dramatically to lower than 45% for all compounds as shown in Figure 7B and
Table 5. Notably, the presence of compounds 102, 103 and 117 decreased their efflux inhibition
more significantly than others possibly due to their working concentrations in this assay were
between 0.75 and 1.5μM while others require more than 1.5μM to be effective. Therefore, unlike
Figure 6, Figure 7 shows similar % efflux inhibitions for all compounds.

Cell Line Treated
with Compounds
(1.5µM)

RFU Slope of
Calcein
Accumulation

% Efflux
Inhibition

DU145/DMSO

11132±847

100±8

TXR/102

5400±157

44±1

TXR/103

3776±90

28±1

TXR/117

4897±170

39±1

TXR/29

3960±123

30±1

TXR/VPL

4951±123

40±1

TXR/DMSO

883±198

0±0

Table 5 Quantitation of P-gp efflux rate inhibition by experimental compounds at 0.75µM in
TXR cells indicated by the accumulation of calcein-AM.
DU145TXR cells were incubated with 2µM calcein-AM for 45 minutes with or without 1.5µM
P-gp inhibitory compounds 102, 103, 117, 29, and verapamil. DU145 cell line was incubated
with 2µM calcein-AM for 45 minutes with DMSO only. The slope for each curve from Figure
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7A with standard deviation was acquired from the linear regression. P-gp efflux inhibition was
calculated using equation % Efflux Inhibition = (RFU slopecompound - slope TXR) / (slopeDU145 slopeTXR) x 100. It represents the mean (n≥6) of at least two independent experiments ± standard
deviation. The efflux rate of DU145TXR was set to 100% and that of the not P-gp
overexpressing DU145 was set to 0%.
2.5 P-gp Inhibitors prevent the migration of TXR cells in the presence of
chemotherapeutics
The ability of cancer cells migrating to other parts within a body is critical in the
metastatic progression of cancers [16]. It was therefore important to investigate whether our
newly discovered, experimental compounds also inhibited migration of TXR cells in culture in
the presence of vinblastine (VIN), a drug that prevents cell migration. A wound healing assay
was used to mimic the migration of cancer cells inside our body as described in [64]. TXR cells
were grown until confluent in 48-well plates and a scratch was made in the middle of the well
from top to bottom using the tip of a pipette. Cells were then treated with chemotherapeutic, VIN
(100nM) alone, P-gp inhibitors 102, 103 (at 2 or 4µM concentrations) and 117 (at 1 or 3µM
concentrations) alone or as combinations of VIN and compounds. The concentrations of
compounds used here were chosen based on their inhibition in viability assays and calcein-AM
accumulation assays. The % wound closure was calculated as the difference between the areas of
scratch zones at t = 0h and t = 23h divided by the area of scratch zone at t = 0h. The scratched
area was quantified using ImageJ, and the data was summarized in Figure 11. DMSO and VIN
only treated cells were used as positive and controls, respectively.
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DMSO

VIN (100nM) alone

102 (2µM) alone

t=0h

t=24h

102 (4µM) alone

102 (2µM) + VIN (100nM)

102 (4µM) + VIN (100nM)

t=0h

t=24h

Figure 8 Experimental compounds 102 prevents the migration of DU145 TXR cells in the
presence of vinblastine (VIN).
TXR cells were grown until confluent in 48-well plates and a scratch was made in the middle of
the well from top to bottom. Images were taken every 60 minutes for 23 hours. Cells were
treated with chemotherapeutic, vinblastine (VIN, 100nM) or P-gp inhibitors 102 (2 or 4µM)
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alone or in combination. Top row in each panel represents the scratch at t = 0 hours outlined as
above. Bottom row in each panel represents t =24 hours.
103 (4µM) alone

103 (2µM) + VIN (100nM)

103 (4µM) + VIN (100nM)

t=0h

t=24h

DMSO

VIN (100nM) alone

103 (2µM) alone

t=0h

t=24h
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Figure 9 Experimental compounds 103 prevents the migration of DU145 TXR cells in the
presence of vinblastine (VIN).
TXR cells were grown until confluent in 48-well plates and a scratch was made in the middle of
the well from top to bottom. Images were taken every 60 minutes for 23 hours. Cells were
treated with chemotherapeutic, vinblastine (VIN, 100nM) or P-gp inhibitors 103 (2 or 4µM)
alone or in combination. Top row in each panel represents the scratch at t = 0 hours outlined as
above. Bottom row in each panel represents t =24 hours.
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Figure 10 Experimental compounds 117 prevents the migration of DU145 TXR cells in the
presence of vinblastine (VIN).
TXR cells were grown until confluent in 48-well plates and a scratch was made in the middle of
the well from top to bottom. Images were taken every 60 minutes for 23 hours. Cells were
treated with chemotherapeutic, vinblastine (VIN, 100nM) or P-gp inhibitors 117 (1 or 3µM)
alone or in combination. Top row in each panel represents the scratch at t = 0 hours outlined as
above. Bottom row in each panel represents t =24 hours.

Figure 11 Summary of the migration data from Figure 8-10.
% wound closure is calculated as the difference between the areas of scratch zones at t = 0h and t
= 23h divided by the area of scratch zone at t = 0h. The area of scratch zone is determined by the
area where no cells are present. The edge of the area is drawn manually, and the area is
calculated automatically by Imager. DMSO (0.5%) treated is set as 100%. It represents the mean
(n≥6) of at least two independent experiments with standard deviation error bars.
VIN or compounds only at any concentration was not able to inhibit the wound closure
by more than 30% as shown in Figure 8-11, indicating that VIN or compounds themselves were
not preventing the migration of TXR cells effectively. However, a combination of VIN and our
compounds at either concentration inhibited the wound closure by more than 50%, indicating
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that our compounds promote the inhibition of the migration in the presence of VIN. Among the
three compounds here, 102 was the most effective in combination with VIN. At 4µM, 102 is able
to inhibit the wound closure by more than 80% while 70% at 2µM. Compound 103 inhibited the
wound closure by about 70% at 2µM or 4µM. Compound 117 inhibited it by 50-60% depending
on the concentration of it. Although 117 showed the lowest inhibition among the three
compounds at more than 3µM in the presence of VIN, it still was able to inhibit it by more than
20% even in the absence of VIN. Compound 103 is also inhibiting the migration at 4µM by 30%,
but not so much at 2µM.
2.6 Experimental compounds do not increase toxicity of paclitaxel in normal human lung
fibroblast (HFL-1) cells
In order to test whether the experimental compounds affected chemotherapy toxicity in
normal human cells, HFL-1 cells were incubated with a range of paclitaxel (PTX) concentrations
in combination with 2.5µM of compounds 102, 103, 108 and 117. After 24 hours, viability was
determined by the resazurin assay[64]. As shown in Figure12A, none of our novel compounds
added any further toxicity to HFL-1 cells beside the toxicity of PTX itself. It is noticeable that
compounds 102 and 103 were toxic to TXR cells at 10µM but not so at 2.5µM as indicated in
Figure 2. So, if the concentration of 10µM was used in this assay, its toxicity toward HFL-1
cells might also be visible. However, our compounds were not toxic to HFL-1 cells at 2.5µM in
the absence of PTX as shown in Figure 12B.
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Figure 12 Experimental compounds are not toxic to human lung fibroblast HFL-1 cells.
HFL-1 cells were incubated with a range of paclitaxel (PTX) concentrations in combination with
2.5µM of compounds 102, 103, 108 and 117. After 24 hours, viability was determined by the
resazurin assay. A. The viability of HFL-1 cells in the presence of compound only or in
combination with PTX. Data represents the mean (n≥6) of at least two independent experiments
with standard deviation error bars for each data point shown above. (•) represents PTX only and
(▪) represents PTX and compound. The control is DMSO treated as 100% viability. X-axis is the
concentration of PTX in the log mode. For some data points, the error bars are smaller than the
size of their symbols so they are not visible. B. The viability of HFL-1 cells in the presence of
compounds 102, 103, 108 and 117 only. The DMSO treated is set as 100%.
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2.7 Experimental compounds do not change the expression level of P-gp in TXR cells
In order to test if our compounds affected the expression levels of P-gp in P-gp
overexpressing TXR cells, western blot analyses of DU145 TXR cancer cells treated with 5μM
of compounds 102, 103, 108, 117, 120, 123 and vehicle/DMSO were performed using anti-P-gp
and anti-actin antibodies[64] as shown in Figure 13. Besides the top four compounds 102, 103,
108 and 117, compounds 120 and 123 are also included as they inhibit ATPase activities of
purified P-gp (Figure 15) although they are not as inhibitive as the top four compounds in
viability assays. DU145 cells are used as a control of the low level of P-gp expression. Purified
mouse P-gp is used here to verify our antibodies are effective.
As shown in Figure 13, none of our compounds changed the expression level of P-gp in
TXR cells as compared to the DMSO treated. P-gp was not detected in the parental drug
sensitive DU145 prostate cancer cell line due to the minimal expression in this cell line. Purified
mouse P-gp has a smaller molecular weight than human P-gp in TXR cells as it lacks the posttranslational modifications when expressed in yeast. In the lane of the purified mouse P-gp, no βactin is detected. From this figure, we conclude that our compounds do not change the
expression of P-gp in TXR cells, instead, they directly inhibit the activity of P-gp resulting in a
low cell viability and a high paclitaxel accumulation inside cells.

41

Mouse DU145 123

120

117

108

103
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DMSO

Figure 13 P-gp expression is unchanged by compound treatment in DU145 TXR prostate cancer
cell line.
Western blots of DU145 TXR cancer cells treated with 5μM of compounds 102, 103, 108, 117,
120, 123 and vehicle/DMSO were performed using anti-P-gp and anti-actin antibodies. P-gp is
not detected in the parental drug sensitive DU145 prostate cancer cell line. Purified mouse P-gp
is used a control, and no β-actin is detected.
2.8 Accumulation assays for substrates screening for in silico identified potential P-gp
inhibitors
As we know that P-gp is capable of transporting a large variety of molecules[1] and

A

B

E

F

C

D

G

Figure 14 Compounds 108, 117, 120 and 123 are catalytic inhibitors of P-gp and not transport
substrates.
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Quantitative LC-MS/MS analysis of intracellular accumulation of 102 (panel A), 103 (panel B),
108 (panel C), 117 (panel D), 120 (panel E), 123 (panel F) and Daunorubicin (panel G) in
DU145 TXR. Each histogram represents the average ± S.D. (n=6, two independent experiments);
** P < 0.01 – very significant; *P<0.05 – significant; NS – not significant). DNR, daunorubicin;
TQR, tariquidar.
substrates of P-gp are problematic in clinical trials[10], it was of interest to screen out
compounds that are potential substrates of P-gp by using TXR cells. The cellular accumulation
of our compounds was measured in the absence or presence of tariquidar, a strong inhibitor of Pgp, currently in clinical trials[26, 62].
As shown in Figure 14, compounds 102 and 103 showed an increased level of
accumulation in the presence of tariquidar, indicating that they are potential substrates, the
transport of which was inhibited by tariquidar thus leading to more accumulation of them inside
TXR cells. Cellular concentrations of compounds 117, 120 and 123 did not change in the
presence or absence of tariquidar, indicating that they are unlikely to be substrates of P-gp.
Interestingly, compound 108 decreased the accumulation in the presence of tariquidar but the
difference is not statistically significant between compound only and in combination with
tariquidar. Similar to 117, 120 and 123, compound 108 is unlikely to be a substrate of P-gp.
Daunorubicin, a substrate of P-gp, was used as a control to confirm the inhibition of substrate
transport by tariquidar. It is noticed that the fold difference in Daunorubicin treated cells in the
absence and presence of tariquidar is significantly larger than that in compound 102 or 103
treated cells with and without tariquidar. This might indicate that compounds 102 and 103 are
relatively weak substrates if they are in terms of their binding affinities to P-gp. Or they have
other binding sites on P-gp other than the drug/substrate binding domain. Compounds 120 and
123 that inhibited ATPase activity of P-gp are unlikely to be substrates as shown in Figure 15,
which otherwise would likely stimulate the activity.
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2.9 Inhibition of the ATPase activity of purified mouse P-gp by experimental compounds
In order to directly test the inhibition of P-gp by our experimental compounds, ATPase
activity assays of purified mouse P-gp was performed in the presence of experimental
compounds. All compounds that reversed multidrug resistance of DU145TXR cells to paclitaxel
at 10µM were tested, including 101, 102, 103, 104, 108, 109, 111, 112, 117, 119, 120 and 123,
as shown in Figure 15. Compound 19, a previously identified P-gp inhibitor [59], was used as a
control. Verapamil was used as a substrate control as it stimulates the activity.
There were two different versions of mouse P-gp (MDR3Cl) used in these assays, one
with all cysteines replaced with alanines defined as “old P-gp” here [65], and the other one with
cysteines substituted with alanines and other amino acids defines as “optimized P-gp” because
this version of P-gp was more wild-like [66]. The word “old” in this thesis only refers to the
specific version of P-gp, and P-gp only. It is not time related or refers to the P-gp environments,
micelles or nanodiscs. Both the old and optimized P-gp were prepared from the fermenter yeast
cells.
P-gp was solubilized in detergents, DDM and Lyso-PC, the concentration of which was
optimized as described in Chapter 3.1 to increase the sensitivity of P-gp to compounds in
ATPase activity assay.
Nanodiscs are composed of target protein, MSP and lipids. The molar ratio of these
components during preparation is critical for the monomer level of nanodiscs and their activities
[55, 56, 58]. The length of MSPs determines the size of nanodiscs, which may affect the activity
of P-gp. Here we used MSP1E3D1 and MSP1D1 [58] with size differences (28 kDa vs 25 kDa,
respectively) for the assembly to both old and optimized P-gp into nanodiscs.
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Both the basal and verapamil-stimulated activity of P-gp were assessed using P-gp in
micelles and nanodiscs with MSP1E3D1 or MSP1D1.
Figure 15A shows the basal (top panel) and verapamil stimulated (bottom panel) activity
of the old P-gp in micelles. The inhibition or stimulation of the activity of P-gp was defined as
by more than 20% as compared to the DMSO control. Compound 120 inhibited the basal activity
by 43%, while 101, 108, 109, 111, 112, 117 and 122 stimulated it by more than 20%.
Compounds 101, 102, 103, 117, 120 and 123 inhibited the verapamil stimulated activity by more
than 20%, while compounds 108, 109 and 112 even further stimulated it by more than 20%. So,
compound 120 inhibited both the basal and stimulated activity, indicating that it is an inhibitor
but not a substrate of the old P-gp in micelles. Compounds 102, 103 and 123 inhibited the
stimulated activity but did not affect the basal activity, indicating that they are unlikely to be
substrates as well. Compounds 101 and 117 inhibited the stimulated activity although stimulate
the basal activity, indicating that they are unlikely to be substrates because the stimulated activity
would not be inhibited if they were substrates. Compounds 108, 109 and 112 stimulated both the
basal and stimulated activity, so they were likely more substrate-like. Compounds 111 and 122
did not affect the stimulated activity but stimulated the basal activity. So, they may be more
substrate-like or potentially bind to allosteric sites that stimulate the basal activity but do not
change the binding of verapamil. Compounds 104 and 119 did not affect either the basal or
stimulated activity. The mechanisms underlying the inhibition or stimulation of P-gp by our
compounds in the presence or absence of verapamil should be further investigated.
Figure 15B shows the basal (top panel) and verapamil stimulated (bottom panel) activity
of the optimized P-gp in micelles. Compounds 101, 109, 120 and 123 inhibited the basal activity
while 102, 108 and 117 stimulated it. Compounds 101, 102 and 103 inhibited the stimulated
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activity while 108, 109, 111 and 112 further stimulated it. So, compound 101 inhibited both
basal and stimulated activity while 108 stimulated both. Compound 102 stimulated the basal
activity but inhibited the stimulated activity. Compound 103 inhibited the stimulated activity but
did not affect the basal activity, while 117 stimulated the basal activity but did not change the
stimulated activity. Compounds 111 and 112 stimulated the activity in the presence of verapamil
but did not affect the basal activity, while 120 and 123 inhibited the basal activity but did not
change the stimulated activity. The inhibition or stimulation by all these compounds could be
explained using the possible mechanisms as discussed in Fig. 13A. One exception is 109, which
inhibited the basal activity but stimulated the activity in the presence of verapamil. 109 could
bind to an allosteric site that inhibits the basal activity by changing the conformation of P-gp, but
this conformational change favors the binding of verapamil, which leads to the further
stimulation. Again, compounds 104 and 119 did not affect either the basal or stimulated activity.
Figure 15C shows the basal (top panel) and verapamil stimulated (bottom panel) activity
of the old P-gp in nanodiscs (MSP1E3D1). Compound 104 inhibited the basal activity while 101,
102, 103, 108, 109, 111, 112, 117, 120 and 122 stimulated it. All compounds inhibited the
stimulated activity except 122 and no compound stimulated the activity in the presence of
verapamil. So, compound 104 inhibited both the basal and stimulated activity. Compounds 101,
102, 103, 108, 109, 111, 112, 117 and 120 stimulated the basal activity but inhibited the
stimulated activity. Compound 119 inhibited the stimulated activity yet did not affect the basal
activity. Compound 122 stimulated the basal activity but did not affect the stimulated activity.
Compound 123 inhibited the stimulated activity but did not affect the basal activity.
Figure 15D shows the basal (top panel) and verapamil stimulated (bottom panel) activity
of the old P-gp in nanodiscs (MSP1D1). Compounds 104 and 123 inhibited the basal activity
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while 101, 102, 103, 108, 109, 111, 112, 117, 120 and 122 stimulated it. Compounds 102, 103,
104, 108, 109, 111, 117, 119, 120 and 123 inhibite the stimulated activity, and no compounds
stimulated the activity in the presence of verapamil. So, compounds 104 and 123 inhibited both
the basal and stimulated activity. Compounds 102, 103, 108, 109, 111, 117 and 120 stimulated
the basal activity but inhibited the stimulated activity. Compounds 112 and 122 stimulated the
basal activity yet did not affect the stimulated activity. Compound 119 inhibited the stimulated
activity yet did not affect the basal activity.
Figure 15E shows the basal (top panel) and verapamil stimulated (bottom panel) activity
of the optimized P-gp in nanodiscs (MSP1E3D1). Compound 123 inhibited the basal activity
while all compounds stimulated it except 119 and 120. Compounds 104, 111, 117, 119, 120 and
123 inhibited the stimulated activity but no compounds stimulated the activity in the presence of
verapamil. So, compound 123 inhibited both the basal and stimulated activity. Compounds 104,
111 and 117 stimulated the basal activity but inhibited the stimulated activity. Compounds 101,
102, 103, 108, 109, 112 and 122 stimulated the basal activity but did not affect the stimulated
activity. Compounds 119 and 120 inhibited the stimulated activity but did not change the basal
activity. No compounds stimulated the activity in the presence of verapamil.
Figure 15F shows the basal (top panel) and verapamil stimulated (bottom panel) activity
of the optimized P-gp in nanodiscs (MSP1D1). Compounds 104 and 123 inhibited the basal
activity while 101, 102, 103, 108, 109, 111, 112, 117, 120 and 122 stimulated it. Compounds
102, 103, 104, 109, 111, 117, 119, 120 and 123 inhibited the stimulated activity. So, compounds
104 and 123 inhibited both the basal and stimulated activity. Compounds 102, 103, 109, 111, 117
and 120 stimulated the basal activity but inhibited the stimulated activity. Compounds 101, 108,
112 and 122 stimulated the basal activity but did not change the stimulated activity. Compound
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119 did not affect the basal activity but inhibited the stimulated activity. No compounds
stimulated the activity in the presence of verapamil.
All data in Figure 15 are summarized in Table 6. Due to the inconsistency in terms of
stimulation or inhibition by the same compound, activity comparisons will be shown in Chapter
3 between the basal and stimulated, P-gp micelles and nanodiscs, P-gp nanodisc (MSP1E3D1)
and (MSP1D1), and the old and optimized P-gp.
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Figure 15 ATP hydrolysis activity in the presence of compounds using P-gp in micelles and
nanodiscs.
ATP hydrolysis was measured using a coupled enzyme assay using compounds 101, 102, 103,
104, 108, 109, 111, 112, 117, 119, 120, 122, 123. Compound 19, a previously identified P-gp
inhibitor[59], is used a control. Compounds concentration: 25µM. The activity of P-gp in the
presence of DMSO only is used a blank control and is set as 100%. Data represents the mean
(n≥6) of at least two independent experiments using at least two different preparations of
proteins with standard deviation error bars. A. Top panel, the basal activity of the old P-gp in
micelles. Verapamil is used as a substrate control. Bottom panel, the verapamil stimulated ATP
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hydrolysis activity of the old P-gp in micelles. Verapamil concentration: 150µM. B. Top panel,
the basal activity of the optimized P-gp in micelles. Bottom panel, the verapamil stimulated
ATP hydrolysis activity of the optimized P-gp in micelles. Verapamil concentration: 25µM for
the basal activity and 150µM for the stimulated activity. C. Top panel, the basal activity of the
old P-gp in nanodiscs (MSP1E3D1). Bottom panel, the verapamil stimulated ATP hydrolysis
activity of old P-gp in nanodiscs (MSP1E3D1). Verapamil concentration: 150µM. D. Top panel,
the basal activity of the old P-gp in nanodiscs (MSP1D1). Bottom panel, the verapamil
stimulated ATP hydrolysis activity of old P-gp in nanodiscs (MSP1D1). Verapamil
concentration: 150µM. E. Top panel, the basal activity of the optimized P-gp in nanodiscs
(MSP1E3D1). Bottom panel, the verapamil stimulated ATP hydrolysis activity of the optimized
P-gp in nanodiscs (MSP1E3D1). Verapamil concentration: 150µM. F. Top panel, the basal
activity of the optimized P-gp in nanodiscs (MSP1D1). Bottom panel, the verapamil stimulated
ATP hydrolysis activity of the optimized P-gp in nanodiscs (MSP1D1). Verapamil
concentration: 150µM.
Purified P-gp in
Figure 15

Basal/Stimulated Inhibition by
Activity
Compounds

Stimulation by
Compounds

No Effect with
Compounds

A-Old P-gp
Micelles

Basal

120

101, 108, 109,
111, 112, 117,
122

104, 119

Stimulated

101, 102, 103,
117, 120, 123

108, 109, 112

Basal

101, 109, 120,
123

102, 108, 117

Stimulated

101, 102, 103

108, 109, 111,
112

Basal

104

101, 102, 103,
108, 109, 111,
112, 117, 120,
122

Stimulated

101, 102, 103,
104, 108, 109,
111, 112, 117,
119, 120, 123

None

Basal

104, 123

101, 102, 103,
108, 109, 111,
112, 117, 120,
122

Stimulated

102, 103, 104,
108, 109, 111,

None

B-Optimized Pgp Micelles

C-Old P-gp
Nanodiscs
(MSP1E3D1)

D-Old P-gp
Nanodiscs
(MSP1D1)
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104, 119

None

None

117, 119,
120,123
E-Optimized Pgp Nanodiscs
(MSP1E3D1)

F-Optimized Pgp Nanodiscs
(MSP1D1)

Basal

123

101, 102, 103,
104,108, 109,
111, 112, 117,
122

Stimulated

104, 111, 117,
119, 120, 123

None

Basal

104, 123

101, 102, 103,
108, 109, 111,
112, 117, 120,
122

Stimulated

102, 103, 104,
109, 111, 117,
119, 120, 123

none

None

None

Table 6 Summary of compounds that inhibit or stimulate the basal or stimulated activity of P-gp
in micelles or nanodiscs.
The first column is the same as Figure 15A-F. A. the activity of the old P-gp in micelles. B. the
activity of the optimized P-gp in micelles. C. the activity of the old P-gp in nanodiscs
(MSP1E3D1). D. the activity of the old P-gp in nanodiscs (MSP1D1). E. the activity of the
optimized P-gp in nanodiscs (MSP1E3D1). F. the activity of the optimized P-gp in nanodiscs
(MSP1D1).
2.10 Inhibition of ATP binding to purified mouse P-gp using electron spin resonance (ESR)
spectroscopy
In order to explain the inhibition mechanism of the ATPase activity by our experimental
compounds as seen in Figure 15, ATP binding characteristics to P-gp was specifically
investigated in the presence of three experimental compounds. Compounds 102, 103 and 117
that showed inhibition of the activity of P-gp were selected to further investigate their inhibition
of ATP binding to P-gp using an ATP analog, SL-ATP [44-46, 50]. The binding curves of SLATP in the presence of compound 117 is shown in Figure 16. In order to accommodate for the
increase in viscosity of protein samples where P-gp was concentrated in mixed micelle solutions,
standard curves were generated using appropriate detergent containing buffers concentrated to
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the same degree as the protein containing samples. In order to determine the amount of proteinbound SL-ANP (ATP/ADP), a standard curve was generated in the absence of protein where the
signal amplitude of the high-field signal of the free, unbound SL-ATP was plotted against the
known concentration of SL-ATP added. The amount of protein-bound SL-ANP was determined
as the difference between the known total concentration of SL-ATP added and the free spinlabeled nucleotide observed in the experiment in the presence of known amounts of P-gp.
Figure 16A shows the SL-ATP titration in the absence of compounds or verapamil. The
maximum mole bound SL-ATP per mole P-gp was calculated as 1.8±0.1 as shown in Table 7,
which is close to 2, indicating the two ATP binding sites on P-gp were able to bind SL-ATP.
Figure 16B shows the SL-ATP titration in the absence of compounds but in the presence of
150µM verapamil. The maximum mole bound SL-ATP per mole P-gp was again calculated to be
1.8±0.1 (Table 7), which is close to 2 as well, indicating the two ATP binding sites on P-gp were
also accessible to SL-ATP in the presence of verapamil. It therefore can be concluded that
verapamil did not interfere with SL-ATP binding to P-gp. The apparent Kd was also not changed
in the presence of verapamil as compared to Figure 16A (Table 7). Figure 16C shows the SLATP titration in the presence of 25µM compound 117 and 150µM verapamil. The maximum
mole bound SL-ATP per mole P-gp was calculated to be 1.1±0.1 (Table 7), which is about half
the maximum binding in the absence of 117, indicating potentially one of the ATP binding sites
is not accessible to ATP in the presence of by 117. Figure 16D shows the SL-ATP titration in
the presence of 25µM compound 117 only and no verapamil present. The maximum mole bound
SL-ATP per mole P-gp was again calculated as 1.0±0.0 (Table 7), indicating that verapamil did
not affect nucleotide binding inhibition by compound 117. The apparent Kd was not changed in
the presence of 117. Compound 102 reduced the maximum binding of SL-ATP to 1.4±0.1
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(Table 7) with or without verapamil and reduced the apparent Kd to about half of that observed
in the DMSO control. Compound 103 did not change the maximum binding (Table 7) but
decreased the apparent Kd by 1/3 of the DMSO control.

A

B

C

D

Figure 16 Inhibition of SL-ANP binding to P-gp by compounds 102, 103 and 117 in the presence
or absence of substrate VPL.
32µM P-gp, 2.5mM Mg2+. A, SL-ATP titration in the absence of compounds or VPL; B, SLATP titration in the absence of compounds but in the presence of VPL; C, SL-ATP titration in
the presence of 25µM compound 117 and 150µM VPL; D, SL-ATP titration in the presence of
25µM C117 only. The resulting maximum binding and apparent Kd of compounds 102, 103 and
117 are summarized in Table 7. Binding curves for compounds 102 and 103 are not shown.
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Purified Mouse P-

Maximum

Apparent Kd

gp

binding

(µM)

(mol SL-ANP/mol
P-gp)

+ DMSO

1.8±0.1/1.8±0.1

36.7±3.8/36.5±3.2

+ C102

1.4±0.1/1.4±0.1

18.4±4.5/19.8±4.7

+ C103

1.8±0.1/1.9±0.1

23.8±6.0/23.6±5.2

+ C117

1.1±0.1/1.0±0.0

23.5±3.0/17.7±5.4

Table 7 Quantitation of inhibition of SL-ANP binding to P-gp by compounds 102, 103 or 117.
The maximum binding and apparent Kd of compounds 102, 103 and 117 are calculated using
non-linear hyperbola curve fitting with GraphPad Prism 8.0.2. The standard deviation is also
directly derived from GraphPad. The maximum binding is represented as mole SL-ANP per
mole P-gp in the absence/presence of VPL. The values of apparent Kd (µM) are also shown in
the absence/presence of VPL.
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CHAPTER 3
RESULTS COMPOUNDS 11-98

3.1 Effects of P-gp inhibitors on P-gp ATPase activity depend on detergent concentration
Compound 45 inhibited verapamil-stimualted activity of P-gp by 60% [39] where Pglycoprotein was used that had been purified from yeast cells grown fermenters and provided to
us by our collaborator, Ina Urbatsch, Texas Tech University Health Center. However, this
inhibition could not be repeated with the P-gp preparations where the yeast cells were grown in
house and in 2.8 L Fernbach flasks. We hypothesized that protein expression during the not so
well controlled fermentation in Fernbach flasks may have been significantly lower than when the
cells were grown under in fermenters with controlled pH, methanol concentration and O2
saturation. To solubilize the respective membranes, more detergent per P-gp may therefore have
been used, significantly increasing the detergents to protein ratio for the different protein
batches. This increased concentration of detergent may have decreased the actual available
concentration of inhibitor due to partitioning of the inhibitor into empty micelles.
To address this issue two approaches were employed. The first one was to try to increase
the expression of P-gp in yeast cells by substituting our in-house fermenter for Fernbach flask
incubation. The fermenter could more precisely control temperature, pH, dissolved oxygen level
and feeding speed of nutrients that typically increases cell growth and protein expression [67].
The first approach resulted in 40% more expression of P-gp and ~6.7-fold cell mass increase,
which gave ~10-fold increase in protein yield. However, with the traditional amount of
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detergents during the protein preparation, we still did not recover the inhibition by compound 45.
Then, we focused on the second approach.
The second approach was to optimize the amount of detergents used during protein
preparation that could potentially decrease the molar ratio of detergents and proteins. For the
second approach, we optimized the detergent concentration in elution buffer only or in both wash
and elution buffers. We maintained the amount of detergents during solubilization before the
wash step because we speculated that less detergents might decrease the solubilization of
proteins which could dramatically affect the final protein yield.
Figure 17 shows the ATPase activity of P-gp purified with different amounts of
detergents used in the elution buffer. From the blue to orange to grey column, a decreased
amount of detergents were used as indicated in Table 8. “*” indicates that zero detergents were
added in the elution buffer, but there should be remaining detergents from the wash step ahead of
elution. As it is not easy to calculate the final detergents concentration after elution, “*” is used
to indicate the value is not available. Compound 19 was used in this test as its inhition was
repeatable with all P-gp preparations with any detergents amount used. Tariquidar, a potent P-gp
inhibitor [26]), was included into this set of experiments since ATPase inhibition by tariquidar is
controversially discussed in the literature [26, 27, 62, 68-70] and it was interesting to investigate
whether these different results may be related to differing detergent concentration in the
repective P-gp preparations. DMSO treated samples were used as 100% residual activity or 0%
inhibition.
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As shown in Figure 17, more than 10% more inhibition was achieved when no detergent
was added in the elution buffer (grey bar) for compound 19. More than 40% more inhibition is
observed for compound 45 when the DDM concentration drops to 2-2.5% and Lyso-PC drops to
0.2-0.25% (orange columns). A new batch of compound 45 was purchased and included in this
assay to rule out the possible ineffectiveness of the old batch. However, it seemed that the new
batch gave the same result as the old one. The residual activity continued to drop when no
detergents were added in the elution buffer (grey columns). For tariquidar, when no detergents
were added in elution buffer, ~40% inhibition was observed while it showed no inhibition when
the concentration of detergents were higher (blue and orange columns). All together, the data
showed that the inhibition by our compounds and tariquidar depended strongly on the amount of
detergents present in the samples and supported our hypothesis that the relatively hydrophobic
inhibitors may be partitioning into detergent micelles causing lower effective concentration and
therefore lower effect on the protein. Furthermore, this observation is not limited to compund 45,
instead it is more of generic observation, and it applied to other compounds including tariquidar.
Detergent concentration therefore should always be an important consideration with assessing
inhibitor of membrane proteins.
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Figure 17 Effects of P-gp Inhibitors on P-gp ATPase Activity Depend on Detergent
Concentration used in elution of purified P-gp.
From left to right, compound 19, 45 (old batch and new batch) and Tariquidar are inclued in the
ATPase activity of P-gp micelles in the presence of 150 µM verapamil. Within in each
compound, from blue to orange to grey, a decreasing amount of detergents (DDM and Lyso-PC)
are added in the elution buffer during protein purification. The amount of detergents used are
summarized in Table 8 below. DMSO treated P-gp was used as control and set as 100% residual
activity.

Blue
(detergent
rich, w/v %)

Orange
(detergent
moderate,
w/v %)

Grey
(detergent
poor, w/v
%)

DDM

6-7.5

2-2.5

*

Lyso-PC

0.6-0.75

0.2-0.25

*

Table 8 Different amounts of detergents DDM and Lyso-PC in the elution buffer for the
purification of P-gp.
This table corresponds to Figure 17 above, and the amount of DDM and Lyso-PC is summarized
as w/v %. “*” indicates no value available as no detergents are added in the elution buffer and
the residual detergents from previous steps during protein purification can not be estimated.
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Figure 18 Inhibition of the VPL-stimulated activity of P-gp purified in wash buffers and elution
buffers with different detergent concentrations by compound 19, 17, 20 and 45.
Blue: 1/20 of the regular DDM & Lyso-PC concentration; Orange: 1/10 of the regular DDM &
Lyso-PC concentration; Grey: ½ of the regular DDM & Lyso-PC concentration; Yellow, 1/1, the
regular DDM & Lyso-PC concentration. The regular concentration of DDM & Lyso-PC is as
Figure 16 (blue column). A, the effect of inhibition of the stimulated activity of P-gp by
compound 19 and 45; B, the effect of inhibition of the stimulated activity of P-gp by compound
17 and 20. DMSO treated P-gp in the same detergents concentrations as compounds treated is
used as control and set as 100% residual activity.
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In order to more precisely control the amount of detergents in the final protein
preparation, the amount of detergents were optimized starting from the wash step instead of the
elution step only, as shown in Figure 18, and the amount of detergents used were further
decreased. In this test, compound 45 along with compound 17, 20 and 42 were investigated.
Similar to the previous results with optimization of detergents concentration in elution buffer
only, with less detergents in the wash and elution buffers, more inhibition was observed (from
yellow to grey to orange to blue, right to left).
3.2 Detergent concentration can be lowered without losing activity
The activity of P-gp in micelles with different concentrations of detergents was assessed
in the presence or obsence of VPL, as shown in Figure 19. From left to right, the concentration
of detergents (DDM and Lyso-PC) used in the wash and elution buffers decreases from 6-7.5%
(w/v) to 0.3-0.38% (w/v) for DDM and 0.6-0.75% to 0.03-0.038% for Lyso-PC. For the basal
activity (blue column), except with 0.6-0.75% DDM and 0.12-0.15% Lyso-PC, with all other
concentrations of detergents, they were not significantly different. For the stimulated activity
(orange column), there were no significant differences between all concentrations of detergents.
All together, the detergents concentrations used in our study did not change the activity of P-gp.
Moving forward, the concentration of DDM at 0.3-0.38% (w/v) and Lyso-PC at 0.03-0.038%
(w/v) should be used for the preparation of P-gp micelles.
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Figure 19 Effect of detergent concentration on ATPase activity of P-gp micelles.
From left to right, a decreasing concentration of detergents (DDM and Lyso-PC) are added in the
wash and elution buffer during protein purification. At each concentration, both the basal and
stimulated activities of P-gp are tested in the absence or presence of verapamil. Blue bar: basal
activity without verapamil; orange bar: stimulated activity with 150 µM verapamil. The activity
of 6-7.5% DDM and 0.6-0.75% Lyso-PC is set as 1.
3.3 Detergent concentration can be lowered without losing protein yield
In order to see if the detergents concentration will affect the protein yield during
preparations, four preparations of P-gp with four sets of concentrations of DDM and Lyso-PC as
shown in Figure 20 was assessed and the final protein yield was presented in the Y-axis. As we
can see, there is no significant difference between these preparations.
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Figure 20 Effect of detergent concentration during protein purification on the protein yield.
From left to right, an increasing concentration of detergents are added in the wash and elution
buffers during protein purification. The protein yield with 6-7.5% DDM and 0.6-0.75% Lyso-PC
is set as 1.
3.4 Effect of lipids concentration for nanodisc preparation on the activity of P-gp by
compound 45
Initially, no inhibition by compound 45 on ATPase activity of P-gp reconstituted into
nanodiscs was observed. We hypothesized that the lipid concentration used for nanodisc
reconstitution may sensitize P-gp to compound 45. However, we did not observe P-gp inhibition
when P-gp: MSP: lipids ratios were varied from 1: 10: 500 to 1:10: 50, as shown in Figure 21.
We speculated that since nanodiscs have a more defined structure than micelles, they may
require a certain amount of lipids for efficient assembly of nanodiscs to occur, the size of which
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is determined the the size of MSPs. Therefore, although different amounts of lipids were used for
nanodiscs assembly, the actual amount of lipids inside the nanodiscs may still be consistent if the
nanodiscs are successfully assembled. This is different from micelles formation, which depend

Residual Activity (% DMSO)

directly on the concentration of detergent.
140%

120%
100%
80%

60%
40%
20%

0%
DMSO

45
45
45
45
(1:10:500) (1:10:200) (1:10:100) (1:10:50)

Figure 21 Effect of lipids concentration for nanodisc preparation on the activity of P-gp in the
presence of compound 45.
From left to right in the presence of compound 45, 500-, 200-, 100-, and 50-fold of lipids are
added during nanodisc assembly as compared to P-gp. The ATPase activity is performed in the
presence of 150 µM verapamil. DMSO treated P-gp activity is set as 100%.
3.5 Comparison of specific activities between nanodisc assemblies with MSP1E3D1 and
MSP1D1
Nanodiscs are composed of target protein, MSP and lipids. The molar ratio of these
components during preparation is critical for the monomer level of nanodiscs and their activities
[58]. The length of MSPs determines the size of nanodiscs, which may affect the activity of P-gp.
Here we used MSP1E3D1 and MSP1D1 [58] with size differences (28 kDa vs 25 kDa,
respectively) for this comparison study. 1:10:250 and 1:10:500 of protein: MSP: lipids ratios
were used for the nanodisc assembly.
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As shown in Figure 22A, the basal activities of P-gp in nanodiscs with MSP1E3D1 at
1:10:250 and 1:10:500 ratios were comparable with a 6-8-fold increase when compared to P-gp
in micelles. And their activities were also similar to the activity of P-gp with MSP1D1 at
1:10:250 ratio. However, the basal activity of P-gp with MSP1D1 at 1:10:500 ratio was about 2fold of P-gp with MSP1D1 at 1:10:250 ratio, indicating that the amount of lipids used for the
nanodiscs assembly with MSP1D1 significantly affected the basal activity of P-gp nanodiscs.
Similarly, the stimulated activity of P-gp in nanodiscs with MSP1D1 at 1:10:500 was twice the
activity of the P-gp with MSP1D1 at 1:10:250 as shown in Figure 22B. The stimulated activity
of P-gp in nanodiscs with MSP1E3D1 was comparable to that with MDP1D1 at 1:10:250.
Altogether, the nanodisc assembly of P-gp with MSP1D1 relied more on the amount of lipids
than that with MSP1E3D1 for both the basal and stimulated activity assays.
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Figure 22 Comparison of Specific Activities between Nanodisc Assemblies with MSP1E3D1
and MSP1D1.
A, basal activity of P-gp nanodiscs assembled with MSP1E3D1 and MSP1D1, and lipids with
250- and 500-fold of P-gp. The basal activity of micelles used for the nanodisc assembly is set as
100%. B, stimulated activity of P-gp nanodisc in the presence of 150 µM, assembled with
MSP1E3D1 and MSP1D1, and lipids with 250- and 500-fold of P-gp. The stimulated activity of
micelles used for the nanodisc assembly is set as 100%.
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3.6 P-gp in micelles and nanodiscs
The specific activity of P-gp in micelles and nanodiscs (with MSP1E3D1) was compared
in the absence or presence of verapamil, as shown in Table 9. Two sets of P-gp micelles were
used for four nanodisc assemblies. The specific basal activity of P-gp micelles was determined to
be 12-16 nmol/min/mg, and the specific stimulated activity was 294-694 nmol/min/mg. The
stimulation of P-gp micelles by 150 µM verapamil was more than 20 fold. The specific basal
activity of P-gp nanodiscs was determined to be 352-642 nmol/min/mg, and the specific
stimulated activity was 831-2100 nmol/min/mg. The stimulation of P-gp nanodiscs by verapamil
was 2-3 fold. The basal activity of P-gp nanodiscs was comparable to the stimualted activity of
P-gp micelles, possibly because P-gp nanodiscs were stimulated by one of their components,
lipid used for assembly [58] or because the scaffold protein MSP, served as a belt for nanodiscs,
changes the conformation of P-gp by bringing the nucleotide binding domains closer to each
other that facilited the ATP binding, which eventually increased the activity [71]. The 2-3 fold
stimulation of nanodiscs in the presence of 150 µM verapamil was comparable to the work by
[68].
The protein recovery after nanodisc assemby from micelles was between 67-82%. The loss of
proteins was probably due to an incomplete assembly or because more than two P-gp molecules
were incorporated into one nanodiscs (the estimated P-gp to nanodisc ratio was ~2.3 by
densotometry on SDS-PAGE gel). Since the 67-82% recovery was calculated based on a ratio of
2, the actual recovery should be more than 67-82%.
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Total drug
stimulated
activity
(nmol/min)

Specific drug
stimulated
Specific basal
activity
activity
(nmol/min/mg)
(nmol/min/mg)

-

-

12

294

205

348

490

831

207.5

431

573

1188

-

-

16

694

264

826

642

2100

280

1070

352

1346

Samples

P-gp yield Total basal
activity
(nmol/min)

P-gp in micelles 1

-

P-gp in nanodisc
74%
(preparation 1-1)
P-gp in nanodisc
82%
(preparation 1-2)
P-gp in micelles 2

-

P-gp in nanodisc
67%
(preparation 2-1)
P-gp in nanodisc
(preparation 2-2)

71%

Table 9 A representative of the activity of P-gp in micelles and nanodiscs.
Two sets of P-gp micelles were used for four nanodisc assemblies. P-gp in nanodisc 1-1 and 1-2
is from P-gp in micelle 1, and P-gp in nanodisc 2-1 and 2-2 is from P-gp in micelle 2. The total
and specific activity of P-gp in the absence (basal) or presence (stimulated) activity of 150 µM
verapamil is included in this table.
3.7 Biochemical evaluation of inhibition mechanisms by compound 11-98
In previous work we assessed a set of potential inhibitors, compounds 11-98 for reversal
of multidrug resistance of DU145TXR cells to paclitaxel [42]. In order to evaluate the type of
inhibition of P-gp by those compounds, we performed ATPase activity assays using purified
mouse P-gp as shown in Figure 23-28. Compound 19, a previously identified P-gp inhibitor[59],
was used as a control, and verapamil was used as a substrate control for stimulated activity.
Typically, P-gp was solubilized in mixed micelles composed of two detergents, DDM
and lyso-PC [39]. But since compounds could potentially partition in micelles (unpublished, see
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the discussion about compound 45), P-gp was functionally reconstituted into lipid bilayer
nanodiscs [72], which were considered to be more native-like and might cause less partitioning
of compounds. Therefore, both mixed micelles and nanodiscs were employed to evaluate the
inhibition of P-gp by compounds, followed by a comparison between these two environments for
P-gp. For nanodiscs assembly of P-gp, two versions of membrane scaffold protein (MSP),
MSP1E3D1 and MSP1D1, were used to see if the size of nanodics would affect the inhibition
test in the presence of our compounds. MSP1E3D1 has a MW of 28kDa, which is slightly larger
than MSP1D1 with 25kDa [72, 73]. All compounds were tested in their inhibition of both basal
and stimulated activity of P-gp. The stimulated activity means a substrate of P-gp, verapamil, is
added this assay, while the basal activity has no substrates present [59]. The stimulated activity
may indicate potential inhibitors of P-gp if it is inhibited, while the basal activity may mainly
shed light on the potential substrates or stimulators of P-gp if it’s stimulated.
The data was summarized in Table 10 and Table 11. In Table 10, compounds that
showed the same effect, either inhibition, stimulation or no effect, were grouped in the same cell
for each scenario considering micelles/nanodiscs, basal/stimulated activity, old/optimized P-gp
and MSP1E3D1/MSP1D1 nanodiscs. In Table 11, individual compounds were analyzed in terms
of their inhibition or stimulation of the basal or stimulated activity of P-gp. The differences
between micelles and nanodiscs, old and optimized P-gp or MSP1E3D1 and MSP1D1 nanodiscs
were not taken into consideration in order to see the overall effect of individual compounds on
the basal or stimulated activity and sort out potential inhibitors and stimulators. It was noted in
Figure 25-28 that several compounds were not tested for their effects on the basal activity of Pgp in nanodiscs, except compound 19, 22, 36, 41, 42, 43, 46 and 66. The main reason was that in
the basal activity assay using P-gp or optimized P-gp nanodiscs, we barely found any inhibition
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by our compounds except compound 19 (Table 10). In addition, as compared to compound 22,
36, 41, 42, 43 and 66, other compounds were less effective in DU145TXR cancer cell screening.
Therefore, it did not seem to be not of importance to test these compounds in the basal activity
using P-gp or optimized P-gp nanodiscs. These data are therefore missing in Table 11. In Table
11, the inhibition, stimulation or no effect was counted for individual compound. Based on the
counting in the stimulated activity, the following 17 compounds were predicted to be more
inhibitor-like: 19, 22, 30, 36, 41, 42, 43, 45, 50, 51, 60, 61, 66, 71, 74, 78 and 79. And compound
17, 26, 32, 54 and 96 were more stimulator-like. Due to the missing data in the basal activity for
some compounds, they were not predicated against substrates. But the predicted stimulators here
were more substrate-like. However, due to the inconsistency in terms of stimulation or inhibition
by the same compound, composed activity comparisons will be done later between the basal and
stimulated, P-gp in micelles and nanodiscs, P-gp nanodisc (MSP1E3D1) and (MSP1D1), and the
old and optimized P-gp.
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Figure 23 ATP hydrolysis activity in the presence of compound 11-98 using P-gp micelles.
ATP hydrolysis was measured using a coupled enzyme assay using compounds 15, 17, 19, 20,
22, 26, 30, 31, 32, 34, 36, 41, 42, 43, 45, 49, 50, 51, 52, 53, 54, 55, 56, 60, 61, 66, 71, 74, 78, 79
and 96. Compounds concentration: 25µM. Verapamil concentration: 150µM. A. Top panel, the
verapamil stimulated activity of P-gp micelles. Bottom panel, the basal ATP hydrolysis activity
of P-gp micelles. Verapamil was used as a substrate control. The activity of P-gp micelles in the
presence of DMSO only was used a blank control and was set as 100%. Data represents the mean
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(n≥6) of at least two independent experiments using at least two different preparations of
proteins with standard deviation error bars.
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Figure 24 ATP hydrolysis activity in the presence of compound 11-98 using optimized P-gp
micelles.
ATP hydrolysis was measured using a coupled enzyme assay using compounds 15, 17, 19, 20,
22, 26, 30, 31, 32, 34, 36, 41, 42, 43, 45, 49, 50, 51, 52, 53, 54, 55, 56, 60, 61, 66, 71, 74, 78, 79
77

and 96. Compounds concentration: 25µM. Verapamil concentration: 150µM. A. Top panel, the
verapamil stimulated activity of optimized P-gp micelles. Bottom panel, the basal ATP
hydrolysis activity of optimized P-gp micelles. Verapamil was used as a substrate control. The
activity of optimized P-gp micelles in the presence of DMSO only was used a blank control and
was set as 100%. Data represents the mean (n≥6) of at least two independent experiments using
at least two different preparations of proteins with standard deviation error bars.
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Figure 25 ATP hydrolysis activity in the presence of compound 11-98 using P-gp nanodiscs with
MSP1E3D1.
ATP hydrolysis was measured using a coupled enzyme assay using compounds 15, 17, 19, 20,
22, 26, 30, 31, 32, 34, 36, 41, 42, 43, 45, 49, 50, 51, 52, 53, 54, 55, 56, 60, 61, 66, 71, 74, 78, 79
and 96. Compounds concentration: 25µM. Verapamil concentration: 150µM. A. Top panel, the
verapamil stimulated activity of P-gp nanodiscs. Bottom panel, the basal ATP hydrolysis
activity of P-gp nanodiscs. Only compound 22, 36, 41, 42, 43, 45 and 66 were included.
Verapamil was used as a substrate control. The activity of P-gp nanodiscs with MSP1E3D1 in
the presence of DMSO only was used a blank control and was set as 100%. Data represents the
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mean (n≥6) of at least two independent experiments using at least two different preparations of
proteins with standard deviation error bars.
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Figure 26 ATP hydrolysis activity in the presence of compound 11-98 using P-gp nanodiscs with
MSP1D1.
ATP hydrolysis was measured using a coupled enzyme assay using compounds 15, 17, 19, 20,
22, 26, 30, 31, 32, 34, 36, 41, 42, 43, 45, 49, 50, 51, 52, 53, 54, 55, 56, 60, 61, 66, 71, 74, 78, 79
and 96. Compounds concentration: 25µM. Verapamil concentration: 150µM. A. Top panel, the
verapamil stimulated activity of P-gp nanodiscs with MSP1D1. Bottom panel, the basal ATP
hydrolysis activity of P-gp nanodiscs with MSP1D1. Only compound 22, 36, 41, 42, 43, 45 and
66 were included. Verapamil was used as a substrate control. The activity of P-gp nanodiscs with
MSP1D1 in the presence of DMSO only was used a blank control and was set as 100%. Data
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represents the mean (n≥6) of at least two independent experiments using at least two different
preparations of proteins with standard deviation error bars.
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Figure 27 ATP hydrolysis activity in the presence of compound 11-98 using optimized P-gp
nanodiscs with MSP1E3D1.
ATP hydrolysis was measured using a coupled enzyme assay using compounds 15, 17, 19, 20,
22, 26, 30, 31, 32, 34, 36, 41, 42, 43, 45, 49, 50, 51, 52, 53, 54, 55, 56, 60, 61, 66, 71, 74, 78, 79
and 96. Compounds concentration: 25µM. Verapamil concentration: 150µM. A. Top panel, the
verapamil stimulated activity of optimized P-gp nanodiscs with MSP1E3D1. Bottom panel, the
basal ATP hydrolysis activity of optimized P-gp nanodiscs with MSP1E3D1. Only compound
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22, 36, 41, 42, 43, 45 and 66 were included. Verapamil was used as a substrate control. The
activity of optimized P-gp nanodiscs with MSP1E3D1 in the presence of DMSO only was used a
blank control and was set as 100%. Data represents the mean (n≥6) of at least two independent
experiments using at least two different preparations of proteins with standard deviation error
bars.
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Figure 28 ATP hydrolysis activity in the presence of compound 11-98 using optimized P-gp
nanodiscs with MSP1D1.
ATP hydrolysis was measured using a coupled enzyme assay using compounds 15, 17, 19, 20,
22, 26, 30, 31, 32, 34, 36, 41, 42, 43, 45, 49, 50, 51, 52, 53, 54, 55, 56, 60, 61, 66, 71, 74, 78, 79
and 96. Compounds concentration: 25µM. Verapamil concentration: 150µM. A. Top panel, the
verapamil stimulated activity of optimized P-gp nanodiscs with MSP1D1. Bottom panel, the
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basal ATP hydrolysis activity of optimized P-gp nanodiscs with MSP1D1. Only compound 22,
36, 41, 42, 43, 45 and 66 were included. Verapamil was used as a substrate control. The activity
of optimized P-gp nanodiscs with MSP1D1 in the presence of DMSO only was used a blank
control and was set as 100%. Data represents the mean (n≥6) of at least two independent
experiments using at least two different preparations of proteins with standard deviation error
bars.
Purified P-gp in
Figure 22-27

Stimulated/Basal Inhibition by
Activity
Compounds

Stimulation by
Compounds

No Effect with
Compounds

17, 22, 30, 36,
41, 42, 43, 45,
50, 60, 61, 66,
71, 74, 96

54

15, 20, 26, 31,
32, 51, 78, 79

Basal

19, 36, 41, 42,
43

15, 17, 20, 22,
26, 30, 31, 32,
50, 51, 54, 60,
61, 71, 78, 79,
96

45, 66, 74

Stimulated

19, 36, 41, 42,
43, 45, 66

17, 26, 32, 51,
54, 74, 78, 96

15, 20, 22, 30,
31, 50, 60, 61,
71, 79

Basal

19, 36, 41, 42,
43

15, 17, 22, 26,
30, 31, 32, 50,
51, 54, 60, 61,
66, 71, 74, 78,
79, 96

20, 45

19, 22, 41, 49,
50, 51, 52, 53,
55, 60, 61, 71,
74, 78

26, 32

15, 17, 20, 30,
31, 34, 36, 42,
43, 45, 54, 56,
66, 79, 96

19

22, 36, 41, 42,
43, 45

None

19, 22, 34, 41,
43, 49, 50, 51,
52, 53, 55, 60,
61, 71, 74, 78,79

26, 32

15, 17, 20, 30,
31, 36, 42, 45,
54, 56, 66, 96

19

22, 36, 41, 42,
43, 45

None

Figure 23-Old P- Stimulated
gp Micelles

Figure 24Optimized P-gp
Micelles

Figure 25-Old P- Stimulated
gp Nanodiscs
(MSP1E3D1)
Basal
Figure 26-Old P- Stimulated
gp Nanodiscs
(MSP1D1)
Basal
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Figure 27Optimized P-gp
Nanodiscs
(MSP1E3D1)

Figure 28Optimized P-gp
Nanodiscs
(MSP1D1)

Stimulated

19, 22, 34, 36,
41, 42, 43, 49,
50, 51, 52, 53,
55, 60, 61, 74,
78, 79

17, 26, 32

15, 20, 30, 31,
45, 54, 56, 66,
71, 96

Basal

19

22, 36, 41, 42,
43, 45

None

Stimulated

19, 22, 34, 36,
41, 42, 43, 49,
50, 51, 52, 53,
55, 60, 61, 74,
78, 79

17, 32, 96

15, 20, 26, 30,
31, 45, 54, 56,
66, 71

Basal

19

36, 41, 42, 43,
45

22

Table 10 Summary of compounds 11-98 that inhibit or stimulate the basal or stimulated activity
of P-gp in micelles or nanodiscs.
The first column is the same as Figure 23-28. Figure 23. the activity of Old P-gp micelles.
Figure 24. the activity of optimized P-gp micelles. Figure 25. the activity of Old P-gp nanodiscs
(MSP1E3D1). Figure 26. the activity of Old P-gp nanodiscs (MSP1D1). Figure 27. the activity
of optimized P-gp nanodiscs (MSP1E3D1). Figure 28. the activity of optimized P-gp nanodiscs
(MSP1D1).
Compound

Stimulated/Basal
Activity

Inhibition
(Times)

Stimulation
(Times)

No effect
(Times)

15

Stimulated

0

0

6

Basal

0

2

0

Stimulated

1

3

2

Basal

0

2

0

Stimulated

6

0

0

Basal

6

0

0

Stimulated

0

0

6

Basal

0

1

1

Stimulated

5

0

1

Basal

0

5

1

17

19

20

22
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26

30

31

32

36

41

42

43

45

50

51

54

60

61

66

Stimulated

0

4

2

Basal

0

2

0

Stimulated

1

0

5

Basal

2

2

0

Stimulated

0

0

6

Basal

0

2

0

Stimulated

0

5

1

Basal

0

2

0

Stimulated

4

0

2

Basal

2

4

0

Stimulated

6

0

0

Basal

2

4

0

Stimulated

4

0

2

Basal

2

4

0

Stimulated

5

0

1

Basal

2

4

0

Stimulated

2

0

4

Basal

0

4

2

Stimulated

5

0

1

Basal

0

2

0

Stimulated

4

1

1

Basal

0

2

0

Stimulated

0

2

4

Basal

0

2

0

Stimulated

5

0

1

Basal

0

2

0

Stimulated

5

0

1

Basal

0

2

0

Stimulated

2

0

4

85

71

74

78

79

96

Basal

0

1

1

Stimulated

3

0

3

Basal

0

2

0

Stimulated

5

1

0

Basal

0

1

1

Stimulated

4

1

1

Basal

0

2

0

Stimulated

3

0

3

Basal

0

2

0

Stimulated

1

2

3

Basal

0

2

0

Table 11 Summary of the inhibition or stimulation of the basal or stimulated activity of P-gp by
individual compound 11-98.
The counting was performed for each compound from Figure 23-28 that showed inhibition,
stimulation or no effect. This indicated the overall effect on the basal and stimulated activity of
P-gp our compounds exhibited without considering how P-gp or optimized was prepared, either
in micelles or nanodiscs, nanodiscs with MSP1E3D1 or MSP1D1.
3.8 Biochemical evaluation of inhibition mechanisms by compound 29 variants
Compound 29 inhibits ATPase activity of mouse P-gp but does not inhibit the ATP
binding from ESR studies [39]. Therefore, compound 29 is considered to be an allosteric
inhibitor of P-gp. Given the fact that there is considerable space available for more interactions
between P-gp and compound 29, several compound 29 variants are created aiming to increase
their binding affinity to P-gp. A novel computer-aided, structure-based software called ChemGen
is used to create three new variants, compound 216, 227 and 231. These three compounds are
selected not to bind to the drug binding domain. Another structure-based rational design leads us
to synthesize five more variants, compound 238, 255, 278, 280 and 286. These variants are not
computationally screened against the drug binding domain, but chosen mainly for the shape, size
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and the physicochemical characteristics, such as solubility and polar surface areas [74]. All eight
variants are assessed for reversal of multidrug resistance using DU145TXR cell line [74].
In order to directly test the inhibition of purified P-gp by these 29 variants, similar to
Chapter 3.7, ATPase activity assays of purified mouse P-gp were performed as shown in Figure
29-34. Compound 19, a previously identified P-gp inhibitor[59], was used as a control. When
basal activity of P-gp was evaluated, verapamil was used as a substrate control for stimulation of
the activity. Figure 29-34 shows verapamil stimulated (top panel) and the basal (bottom panel)
activity of the P-gp in micelles (Figure 29), in optimized P-gp micelles (Figure 30), in P-gp
nanodisc with MSP1E3D1 (Figure 31), in P-gp nanodisc with MSP1D1 (Figure 32), in
optimized P-gp nanodisc with MSP1E3D1 (Figure 33) and in optimized P-gp nanodisc with
MSP1D1 (Figure 34), respectively. The inhibition or stimulation of the activity of P-gp was
defined as reduction or stimulation by more than 20% as compared to the DMSO control and the
effects of compound 29 and 29 variants were summarized in Table 12 in three categories:
inhibition, stimulation and no effect (no significant stimulation or inhibition).
The data indicated that 29 inhibited the stimulated activity of P-gp in P-gp micelles,
optimized P-gp micelles, P-gp nanodisc with MSP1E3D1 and optimized P-gp nanodisc with
MSP1D1, while it had no significant effect on stimulated activity of P-gp nanodisc with
MSP1D1, optimized nanodisc P-gp with MSP1E3D1 or the basal activity of P-gp or optimized
P-gp in micelles or nanodiscs. These observations indicated that compound 29 was likely an
inhibitor of P-gp and likely not a substrate.
Compound 216 inhibited stimulated activity of P-gp in old nanodiscs with MSP1D1 and
optimized P-gp in nanodiscs with MSP1D1. However, it stimulated the basal activity of P-gp in
nanodiscs with MSP1E3D1and MSP1D1. But in most cases, it showed no effect. This indicated
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that compound 216 was unlikely to be a substrate because the stimulated activity would not be
inhibited if it was a substrate.
Compound 227 inhibited all stimulated activities of P-gp in micelles and nanodiscs and it
even inhibited the basal activity of optimized P-gp in micelles. However, it stimulated the basal
activity of p-gp in P-gp nanodisc with MSP1E3D1 and MSP1D1. It showed no effect on the
basal activities of P-gp micelles or optimized P-gp nanodisc with MSP1E3D1 or MSP1D1. So,
compound 227 was unlikely a substrate of P-gp because the stimulated activity would not be
inhibited if it was a substrate.
Compound 231 stimulated even the stimulated activity of P-gp micelles but inhibited the
basal activity of P-gp and optimized P-gp micelles. However, it stimulated all basal activity of Pgp and optimized P-gp nanodiscs while inhibiting all stimulated activity of P-gp and optimized
P-gp nanodiscs. Considering these all together, compound 231 was less likely to be a substrate of
P-gp especially in nanodiscs than in micelles.
Compound 238 stimulated all basal activities of P-gp and optimized P-gp in micelles and
nanodiscs. It inhibited the stimulated activity of P-gp nanodisc with MSP1E3D1 and MSP1D1
and optimized P-gp nanodisc with MSP1D1, while it stimulated the activity of P-gp and
optimized P-gp in micelles. So, it was not easy to tell if 238 was a substrate or not as it could
either stimulate or inhibit the stimulated activity of P-gp. But it looked like it really depended on
micelles or nanodiscs where P-gp or optimized P-gp was in because it stimulated the micelles but
inhibited the nanodiscs. In other words, micelles or nanodiscs played an important role in
determining the stimulation or inhibition of P-gp by compound 238.
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Compound 255 inhibited stimulated activity of P-gp nanodiscs with MSP1D1 and
optimized P-gp nanodisc with MSP1D1. But for most cases, it stimulated the basal and
stimulated activity. So statistically, it was more like a substrate than an inhibitor of P-gp. But
MSP1D1 not MSP1E3D1 might contribute to the inhibition of two nanodiscs observed above.
Compound 278 only stimulated the basal activity of P-gp nanodiscs with both
MSP1E3D1 and MSP1D1 and optimized P-gp in nanodiscs with MSP1D1. But in most cases, it
either inhibited or did not affect the activity. So statistically, it was less likely to be a substrate of
P-gp especially in micelles.
Compound 280 either stimulated or did not affect the activity of P-gp and optimized P-gp
micelles. But it inhibited the stimulated activity of P-gp and optimized P-gp nanodisc and the
basal activity of optimized P-gp nanodiscs with MSP1E3D1 and MSP1D1. So, statistically
compound 280 was less likely to be a substrate of P-gp, but micelles or nanodiscs might play an
important role in the determination.
Compound 286 inhibited the stimulated activity of optimized P-gp nanodiscs with
MSP1D1, but stimulated both the basal and stimulated activity of P-gp and optimized micelles as
well as the basal activity of P-gp and optimized P-gp nanodiscs with both MSP1E3D1 and
MSP1D1. In addition, it did not affect the stimulated activity of P-gp nanodiscs or optimized Pgp nanodiscs with MSP1E3D1. So, statistically compound 286 was more likely to be a substrate
of P-gp.
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Stimulated Activity of Old P-gp Micelles

Residual Activity (%DMSO)

250%
200%
150%
100%
50%
0%
C29 C216 C227 C231 C238 C255 C278 C280 C286 DMSO

Basal Activity of Old P-gp Micelles

Figure 29 ATP hydrolysis activity in the presence of compound 29 variants using P-gp micelles.
ATP hydrolysis was measured using a coupled enzyme assay using compound 29 and its variants
216, 227, 231, 238, 255, 278, 280 and 286. Compound 19, a previously identified P-gp
inhibitor[59], is used as a control. Compounds concentration: 25µM. Verapamil concentration:
150µM. Top panel, the verapamil stimulated activity of P-gp micelles. Bottom panel, the basal
ATP hydrolysis activity of P-gp micelles. Verapamil is used as a substrate control. The activity
of P-gp in the presence of DMSO only is used a blank control and is set as 100% residual
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activity. Data represents the mean (n≥6) of at least two independent experiments using at least
two different preparations of proteins with standard deviation error bars.
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Figure 30 ATP hydrolysis activity in the presence of compound 29 variants using optimized P-gp
micelles.
ATP hydrolysis was measured using a coupled enzyme assay using compound 29 and its variants
216, 227, 231, 238, 255, 278, 280 and 286. Compound 19, a previously identified P-gp
inhibitor[59], is used as a control. Compounds concentration: 25µM. Verapamil concentration:
150µM. Top panel, the verapamil stimulated activity of optimized P-gp micelles. Bottom panel,
the basal ATP hydrolysis activity of P-gp micelles. Verapamil is used as a substrate control. The
91

activity of optimized P-gp in the presence of DMSO only is used a blank control and is set as
100% residual activity. Data represents the mean (n≥6) of at least two independent experiments
using at least two different preparations of proteins with standard deviation error bars.
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Figure 31 ATP hydrolysis activity in the presence of compound 29 variants using P-gp nanodiscs
with MSP1E3D1.
ATP hydrolysis was measured using a coupled enzyme assay using compound 29 and its variants
216, 227, 231, 238, 255, 278, 280 and 286. Compound 19, a previously identified P-gp
inhibitor[59], is used as a control. Compounds concentration: 25µM. Verapamil concentration:
150µM. Top panel, the verapamil stimulated activity of P-gp nanodiscs with MSP1E3D1.
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Bottom panel, the basal ATP hydrolysis activity of P-gp nanodiscs with MSP1E3D1. Verapamil
is used as a substrate control. The activity of P-gp in the presence of DMSO only is used a blank
control and is set as 100% residual activity. Data represents the mean (n≥6) of at least two
independent experiments using at least two different preparations of proteins with standard
deviation error bars.

Residual Activity (% DMSO)

Stimulated Activity of P-gp Nanodiscs
(MSP1D1)
120%
100%
80%
60%
40%
20%
0%

Residual Activity (% DMSO)

Basal Activity of P-gp Nanodiscs (MSP1D1)
400%
350%
300%
250%
200%
150%
100%
50%
0%

Figure 32 ATP hydrolysis activity in the presence of compound 29 variants using P-gp nanodiscs
with MSP1D1.
ATP hydrolysis was measured using a coupled enzyme assay using compound 29 and its variants
216, 227, 231, 238, 255, 278, 280 and 286. Compound 19, a previously identified P-gp
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inhibitor[59], is used as a control. Compounds concentration: 25µM. Verapamil concentration:
150µM. Top panel, the verapamil stimulated activity of P-gp nanodiscs with MSP1D1. Bottom
panel, the basal ATP hydrolysis activity of P-gp nanodiscs with MSP1D1. Verapamil is used as
a substrate control. The activity of P-gp in the presence of DMSO only is used a blank control
and is set as 100% residual activity. Data represents the mean (n≥6) of at least two independent
experiments using at least two different preparations of proteins with standard deviation error
bars.
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Figure 33 ATP hydrolysis activity in the presence of compound 29 variants using optimized P-gp
nanodiscs with MSP1E3D1.
ATP hydrolysis was measured using a coupled enzyme assay using compound 29 and its variants
216, 227, 231, 238, 255, 278, 280 and 286. Compound 19, a previously identified P-gp
inhibitor[59], is used as a control. Compounds concentration: 25µM. Verapamil concentration:
150µM. Top panel, the verapamil stimulated activity of optimized P-gp nanodiscs with
MSP1E3D1. Bottom panel, the basal ATP hydrolysis activity of optimized P-gp nanodiscs with
MSP1E3D1. Verapamil is used as a substrate control. The activity of optimized P-gp in the
presence of DMSO only is used a blank control and is set as 100% residual activity. Data
represents the mean (n≥6) of at least two independent experiments using at least two different
preparations of proteins with standard deviation error bars.
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Figure 34 ATP hydrolysis activity in the presence of compound 29 variants using optimized P-gp
nanodiscs with MSP1D1.
ATP hydrolysis was measured using a coupled enzyme assay using compound 29 and its variants
216, 227, 231, 238, 255, 278, 280 and 286. Compound 19, a previously identified P-gp
inhibitor[59], is used as a control. Compounds concentration: 25µM. Verapamil concentration:
150µM. Top panel, the verapamil stimulated activity of optimized P-gp nanodiscs with
MSP1D1. Bottom panel, the basal ATP hydrolysis activity of optimized P-gp nanodiscs with
MSP1D1. Verapamil is used as a substrate control. The activity of optimized P-gp in the
presence of DMSO only is used a blank control and is set as 100% residual activity. Data
represents the mean (n≥6) of at least two independent experiments using at least two different
preparations of proteins with standard deviation error bars.
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Purified P-gp in
Figure 28-33

Stimulated/Basal
Activity

Inhibition by
Compounds

Stimulation by
Compounds

No Effect with
Compounds

Figure 29-Old
P-gp Micelles

Stimulated

29, 227, 278

231, 238, 255,
286

216, 280

Basal

231, 278

238, 255, 280,
286

29, 216, 227

Figure 30Optimized P-gp
Micelles

Stimulated

29, 227

238, 255, 280,
286

216, 231, 278

Basal

227, 231

238, 255, 286

29, 216, 278,
280

Figure 31-Old
P-gp Nanodiscs
(MSP1E3D1)

Stimulated

29, 227, 231,
238, 280

None

216, 255, 278,
286

Basal

None

216, 227, 231,
238, 255, 278,
286

29, 280

Figure 32-Old
P-gp Nanodiscs
(MSP1D1)

Stimulated

216, 227, 231,
238, 255, 278,
280

None

29, 286

Basal

None

216, 227, 231,
238, 255, 278,
286

29, 280

Figure 33Optimized P-gp
Nanodiscs
(MSP1E3D1)

Stimulated

227, 231, 278,
280

None

29, 216, 238,
255, 286

Basal

280

231, 238, 255,
278, 286

29, 216, 227

Figure 34Optimized P-gp
Nanodiscs
(MSP1D1)

Stimulated

29, 216, 227,
231, 238, 255,
278, 280, 286

None

None

Basal

280

231, 238, 255,
286

29, 216, 227,
278

Table 12 Summary of compound 29 variants that inhibit or stimulate the basal or stimulated
activity of P-gp and optimized P-gp micelles or nanodiscs.
The first column is the same as Figure 29-34. Figure 29. the activity of P-gp micelles. Figure
30. the activity of optimized P-gp micelles. Figure 31. the activity of P-gp in nanodiscs
(MSP1E3D1). Figure 32. the activity of P-gp in nanodiscs (MSP1D1). Figure 33. the activity of
optimized P-gp nanodiscs (MSP1E3D1). Figure 34. the activity of optimized P-gp nanodiscs
(MSP1D1).
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3.9 Inhibition of ATP binding to purified mouse P-gp by compound 29 variants
In order to investigate the mechanism of inhibition of ATPase activity by our
experimental compounds as seen in Table 12, the ATP binding characteristics to P-gp was
specifically investigated in the presence of our experimental compounds using electron spin
resonance spectroscopy (ESR). All 29 variants were tested in their inhibition of ATP binding to
P-gp using an ATP analog, SL-ATP. The binding curves of SL-ATP in the presence of
compounds are shown in Figure 35. The amount of protein-bound SL-ATP was determined. In
order to accommodate for the increase in viscosity of protein samples where P-gp was
concentrated in mixed micelle solutions, standard curves were generated using appropriate
detergent containing buffers concentrated to the same degree as the protein containing samples.
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Figure 35 Inhibition of SL-ATP binding to P-gp in the presence of 29-variants 227, 238 and 278
in the presence or absence of substrate verapamil.
32µM P-gp, 2.5mM Mg2+. A, SL-ATP titration with no compounds or verapamil added. B, SLATP titration in the presence of 25µM 29-variant 227 in the presence of 150 µM VPL; C, SLATP titration in the presence of 25µM 29-variant 227 in the absence of VPL. D, SL-ATP
titration in the presence of 25µM 29-variant 238 in the presence of 150 µM VPL; E, SL-ATP
titration in the presence of 25µM 29-variant 238 in the absence of VPL. F, SL-ATP titration in
the presence of 25µM 29-variant 278 in the presence of 150 µM VPL; G, SL-ATP titration in the
presence of 25µM 29-variant 278 in the absence of VPL. The resulting maximum binding and
apparent Kd of all 29 variants are summarized in the Table 13.
The maximum binding stoichiometry and apparent Kd of SL-ANP binding in the
presence of the various inhibitors were presented in Table 10. Except for compounds 238 and
278, none of the novel inhibitors including the newly synthesized compounds 541 and 551,
affected maximal binding of the ATP analog or the apparent Kd. Compounds 238 and 278
reduced SL-ATP binding to about 1 mol SL-ATP bound per mol of enzyme, suggesting that
these inhibitors may also interact with the nucleotide binding sites or may indirectly induce
changes in nucleotide binding to P-gp that affect ATP binding.
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SMU29 Variants

Maximum ATP Binding

Apparent Kd

(mole SL-ATP bound/mole
P-gp)

(µM)

DMSO

1.8±0.1

36.5±3.6

29

1.9±0.1

71.0±12.0

29-216

1.7±0.1

23.1±3.9

29-227

1.8±0.1

36.9±4.1

29-231

1.6±0.1

22.2±3.8

29-238

1.2±0.1

20.1±4.0

29-255

1.9±0.1

25.6±4.7

29-278

1.3±0.1

22.9±4.5

29-280

1.6±0.1

21.6±4.6

29-286

1.9±0.1

25.7±4.9

29-541

1.8±0.1

24.1±4.0

29-551

1.7±0.1

22.8±3.6

Table 13 Quantitation of inhibition of SL-ANP binding to P-gp by compounds 29 variants.
The maximum binding and apparent Kd of compound 29 variants are calculated using non-linear
hyperbola curve fitting with GraphPad Prism 8.0.2. The standard deviation is also directly
derived from GraphPad. The maximum binding is represented as mole SL-ANP per mole P-gp.
3.10 Experimental compounds potentiate paclitaxel cytotoxicity in DU145TXR cell line
Compounds 36, 41, 42 and 43 were preliminarily tested in resazurin assays at 10µM [42],
but it was still of interest to determine their PC50 values using a variety of concentrations. Two
novel compounds 120 and 123 were not titrated in such a manner as they were not top hits from
resazurin assays done in Chapter 2.1. They were included here as they showed strong ATPase
activity inhibition of P-gp in micelles in the presence of VPL as shown in Chapter 2. In order to
assess the capability of these compounds to potentiate the cytotoxicity of paclitaxel to the Pglycoprotein overexpressing prostate cancer cell line, DU145TXR, similar to Chapter 2.3, we
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performed resazurin cell viability assays [63] using a variety of concentrations of compounds 36,
41, 42, 43, 120 and 123 in the assay[63, 64] in the presence of 500 nM PTX (Figure 36). All
these compounds inhibited the ATPase activity of P-gp in micelles in the presence of VPL. Each
compound was represented using defined symbols and colors for data points and their fitted
curves, respectively. The data were normalized to DMSO treated cells in the absence of PTX or
compounds which was set as 100% cell viability. From the fitted curve for each compound,
compound PC50 was derived using nonlinear, four-parameter logistic analysis with GraphPad
Prism 8.0.2. The compound PC50 in µM for all compounds are summarized in Table 14.

Figure 36 Experimental compounds potentiate paclitaxel cytotoxicity in DU145TXR cell line.
TXR cells were incubated with a range of concentrations of experimental compounds 36, 41, 42,
43, 120 and 123 in combination with 500nM PTX. After 48 hours, cell viability was determined
using the resazurin assay. Data represents the mean (n≥6) of at least two independent
experiments with standard deviation error bars for each data point shown above. Each compound
is represented using defined symbols and colors as above for data points and curves,
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respectively. The data was normalized to DMSO treated cells as 100% viability. For some data
points, the error bars are smaller than the size of their symbols.

Compounds

Compounds PC50 (µM)

36

3.5±0.0

41

2.8±0.0

42

1.1±0.6

43

4.3±0.2

120

6.0±1.1

123

6.0±1.5

Table 14 Compounds potentiate paclitaxel cytotoxicity in DU145TXR cell line.
The compound PC50 value for each compound was derived from its curve fitting from the plotted
mean viability presented in Figure 36. using nonlinear, four-parameter logistic analysis as
describe in Methods. Data represents the mean (n≥6) of at least two independent experiments ±
standard deviation. VPL: verapamil.
3.11 Experimental compounds do not change the expression of P-gp in TXR cells
In order to test if our compounds can potentially change the expression of P-gp in P-gp
overexpressing TXR cells, western blots of DU145 TXR cancer cells treated with 5μM of
compounds 29, 34, 45 and vehicle/DMSO were performed using anti-P-gp and anti-actin
antibodies [64] as shown in Figure 37. DU145 cells were used as a control for the low level of
P-gp expression.
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As shown in Figure 37, none of our compounds changed the expression of P-gp in TXR
cells as compared to the DMSO treated. P-gp was not detected in the parental drug sensitive
DU145 prostate cancer cell line due to the minimal expression in this cell line. From this figure,
we concluded that our compounds did not change the expression of P-gp in TXR cells, instead,
they directly inhibited the activity of P-gp resulting in a low cell viability and a high paclitaxel
accumulation inside cells.

Figure 37 P-gp expression is unchanged by compound treatment in DU145 TXR prostate cancer
cell line.
Western blots of DU145 TXR cancer cells treated with 5 μM of compounds (29, 34 or 45) and
vehicle/DMSO were performed using anti-P-gp and anti-actin antibodies. P-gp was not detected
in the parental drug sensitive DU145 prostate cancer cell line.
3.12 Accumulation assays for substrates screening for in silico identified potential P-gp
inhibitors
As we know that P-gp is capable of transporting a large variety of molecules[1] and
substrates of P-gp are problematic in clinical trials [10], it is of interest to screen out compounds
that are potential substrates using TXR cells. The accumulation of our compounds was measured
in the absence or presence of tariquidar, a P-gp inhibitor in clinical trials [26, 62]. Compounds
36, 41, 42 and 43 that inhibit the ATPase activity of P-gp in micelles and reverse the multidrug
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resistance [42] of prostate cancer cell DU145TXR were tested here. Daunorubicin (DNR), a
substrate of P-gp, was used a control to confirm the inhibition of substrate transport by
tariquidar.

A

B

C

D
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Figure 38 Compounds 36, 41, and 43 are catalytic inhibitors of P-gp and not transport substrates.
Quantitative LC-MS/MS analysis of intracellular accumulation of 36 (panel A), 41 (panel B), 42
(panel C), 43 (panel D), or Daunorubicin (panel E) in DU145TXR. Each histogram represents
the average ± S.D. (n=6, two independent experiments). ** P < 0.01 – very significant; *P<0.05
– significant; NS – not significant). DNR, daunorubicin; TQR, tariquidar.
As shown in Figure 38, compound 42 had an increased level of accumulation in the
presence of tariquidar, indicating that it was a potential substrate, the transport of which was
inhibited by tariquidar thus leading to more accumulation of them inside TXR cells. But it was
noticed that the fold difference in compound 42 treated cells in the absence and presence of
tariquidar was significantly smaller than that in daunorubicin treated cells with and without
tariquidar. This might indicate that compound 42 was a relatively weak substrate in terms of its
binding affinity to P-gp. Compounds 36 and 41 did not change in the presence of tariquidar,
indicating that they were unlikely to be substrates of P-gp. Interestingly, compound 43 decreased
the accumulation in the presence of tariquidar, indicating that tariquidar might compete with
compound 43 binding to P-gp. But at least, 43 was unlikely to be a substrate.
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3.13 Activity comparison of old and optimized MDR3Cl in the presence of inhibitory
compounds
Due to the inconsistencies in the ATPase activity test of compounds using old and
optimized P-gp as shown in Figures 23-34 and Table 11-12, it seemed necessary to compare
them statistically to see the whether the similarity and difference between old and optimized Pgp. Basically, the residual activity of old and optimized P-gp was plotted at x- and y-axis,
respectively for each of the inhibitory compound. There were six categories including basal
activity of P-gp in micelles, basal activity of P-gp in nanodiscs-MSP1E3D1 (large, L), basal
activity of P-gp in nanodiscs-MSP1D1 (small, S), stimulated activity of P-gp in micelles,
stimulated activity of P-gp in nanodiscs-MSP1E3D1 (L), and stimulated activity of P-gp in
nanodiscs-MSP1D1 (S) (Figure 39). All compounds that reversed MDR of prostate cancer cell
line DU145TXR to PTX were analyzed. A linear regression curve was generated with values of
the slope and R2, representing the similarity between x and y values and the variation of data
distribution. So, if the slope is closer to 1, the old and optimized P-gp are more similar; if the R2
is closer to 1, the data points are more tightly distributed along the regression curve. Two straight
lines (in red) at x-1 and y=1 were drawn resulting in four zones that represented
inhibition/stimulation (I/S, top left), inhibition/inhibition (I/I, bottom left),
stimulation/stimulation (S/S, top right), and stimulation/inhibition (S/I). Compounds that fell in
zones (I/I) and (S/S) were counted and the added percentage of them together was calculated.
Another zone (-/-) that represented (no effect/no effect) was not separated in the figure, but it
showed compounds that exhibited less than 20% stimulation or inhibition. The sum of
percentage of (I/I), (S/S) and (-/-) represents the positive correlation between the activity of old
and optimized P-gp in response to compounds. Unlike the slope, since this positive correlation
did not take into consideration of the extent of inhibition (I/I) and stimulation (S/S), or the (S/I)
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and (I/S), it might be more practical for the prediction of the relationship between old and
optimized P-gp.
For both basal and stimulated activity of P-gp, the slope values were all more than or
around 0.90 except Figure 39 A and E with slopes less than 0.60, which represented the basal
activity of P-gp micelles and stimulated activity of P-gp nanodiscs (L), respectively. This
indicated that the old and optimized P-gp were pretty similar in response to our compounds in
most cases. However, it seemed they differentiate to some extent in the basal activity of P-gp
micelles and stimulated activity of P-gp nanodiscs (L), indicating that the differences in residues
that replace cysteines in P-gp may be accountable for their different responses to compounds in
such conditions. It was also noticed that the slopes are all less than 1, so the activities of
optimized P-gp were less than those of old P-gp in the presence of compounds. This indicated
that as compared to old P-gp, the optimized P-gp was either inhibited more or stimulated less by
the experimental compounds, especially for those two conditions where slopes of less than 0.60
were observed. The R2 values were more than 0.60 in all cases except for the stimulated activity
of P-gp in nanodiscs (L) and again indicates a tight distribution of data that represents a high
precision in most cases. The data is summarized in Table 15. The average of slope values was
calculated as 0.80, which was almost the same as the % positive correlation (78.2%), shown in
the very right column in Table 15. The values for % (I/I), (S/S) and (-/-) were calculated and
summed up to get the % positive correlation.
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Optimized P-gp Micelles

Basal Activity of P-gp Micelles: Old vs Optimized

Old P-gp Micelles
Basal Activity of P-gp Nanodiscs (L): Old vs Optimized

Optimized P-gp Nanodiscs (L)

B

Slope: 0.91
2
R : 0.60

Old P-gp Nanodiscs (L)

C

Optimized P-gp Nanodiscs (S)

Basal Activity of P-gp Nanodiscs (S): Old vs Optimized

Old P-gp Nanodiscs (S)
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D

Optimized P-gp Micelles

Stimulated Activity of P-gp Micelles: Old vs Optimized

Old P-gp Micelles

E

Optimized P-gp Nanodiscs (L)

Stimulated Activity of P-gp Nanodiscs (L): Old vs Optimized

Old P-gp Nanodiscs (L)

Optimized P-gp Nanodiscs (S)

Stimulated Activity of P-gp Nanodiscs (S): Old vs Optimized

Old P-gp Nanodiscs (S)
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Figure 39 Activity comparison of old and optimized MDR3Cl with compounds.
This includes comparison of old and optimized P-gp in the following categories. (A), basal
activity of P-gp in micelles; (B), basal activity of P-gp in nanodiscs-MSP1E3D1 (large, L); (C),
basal activity of P-gp in nanodiscs-MSP1D1 (small, S); (D), stimulated activity of P-gp in
micelles; (E), stimulated activity of P-gp in nanodiscs-MSP1E3D1 (L); (F), stimulated activity of
P-gp in nanodiscs-MSP1D1 (S).
3.14 Activity comparison of P-gp in micelles and nanodiscs
In Figure 40, the activity of P-gp in micelles and nanodiscs were compared in the
presence of compounds. Both the values of slope and R2 were lower than 0.32, with most of
them lower than 0.20, indicating that there was a poor correlation between P-gp in micelles
compared to P-gp in nanodiscs. In other words, the detergent micelle and the more native-like
lipid nanodisc environments are dramatically different from each other when used in testing the
effects of experimental compounds on P-gp ATPase activity. The reason might be that
compounds have different partitioning characteristics in micelles and nanodiscs; and/or the
different environments, detergent and lipids, affect the conformation of P-gp differently resulting
in different binding affinities for compounds. It was also of notice to state that the slopes were
much less than 1, indicating that P-gp in nanodiscs were much more inhibited or much less
stimulated as compared to P-gp in micelles. This may also mean that P-gp in nanodiscs were
more sensitive to inhibition than stimulation by our compounds.
However, the calculated % positive correlation between micelles and nanodiscs (46.7%,
see Table 15) was higher than the average slope value calculated as 0.19. This indicated that
micelles and nanodiscs were the same in responding to almost 50% of compounds, in terms of
inhibition or stimulation without considering the level of inhibition or stimulation (more than
20% though). Since 50% was still low, it was critical to choose either micelles or nanodiscs in
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these biochemical assays. But in general, since nanodiscs are more native-like, it should be
preferred for use nanodisc reconstituted P-gp for future experiments.
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Optimized P-gp Nanodiscs (L)
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G

H

Optimized P-gp Nanodiscs (S)

Stimulated Activity of Optimized P-gp: Micelles vs Nanodiscs (S)

Optimized P-gp Micelles

Optimized P-gp Nanodiscs (L)

Stimulated Activity of Optimized P-gp: Micelles vs Nanodiscs (L)

Optimized P-gp Micelles

Figure 40 Activity comparison of P-gp in micelles and nanodiscs with compounds.
This includes comparison of P-gp in micelles and nanodiscs in the following categories. (A),
basal activity of old P-gp in micelles and nanodiscs (L); (B), basal activity of old P-gp in
micelles and nanodiscs (S); (C), basal activity of optimized P-gp in micelles and nanodiscs (S);
(D), basal activity of optimized P-gp in micelles and nanodiscs (L); (E), stimulated activity of
old P-gp in micelles and nanodiscs (S); (F), stimulated activity of old P-gp in micelles and
nanodiscs (L); (G), stimulated activity of optimized P-gp in micelles and nanodiscs (S); (H),
stimulated activity of optimized P-gp in micelles and nanodiscs (L).
3.15 Comparison of basal and stimulated activity of P-gp with compounds
In Figure 41, the basal and stimulated activities of P-gp are compared as shown above in
the presence of experimental compounds. All slope values were less than 0.20, indicating a poor
correlation between the basal and stimulated activity of P-gp. It also meant that the stimulated
115

activity of P-gp was more easily inhibited than stimulated as compared to the basal activity.
Therefore, the stimulated activity was more suitable for inhibitor screening while the basal
activity is more appropriate for screening of stimulatory compounds, such as potential substrates
of P-gp. Although the % positive correlation between basal and stimulated activity (24.7%, in
Table 15) was higher than the average slope value (0.12, in Table 15), it was still hard to say
whether the two are correlated. In conclusion, the presence of P-gp substrate VPL significantly
altered the response of P-gp to our compounds, resulting in a poor correlation between the basal
and stimulated activity of P-gp.
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C

Slope: 0.08
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R : 0.29

Activity of Optimized P-gp Micelles: Basal vs Stimulated

Basal Optimized Pgp Micelles

Activity of Optimized P-gp Nanodiscs (L): Basal vs Stimulated

Stimulated Optimized P-gp
Nanodiscs (L)

E

Stimulated Optimized Pgp Micelles

D

Basal Optimized P-gp Nanodiscs (L)
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Activity of Optimized P-gp Nanodiscs (S): Basal vs Stimulated

Stimulated Optimized P-gp
Nanodiscs (S)

F

Basal Optimized P-gp Nanodiscs (S)

Figure 41 Activity comparison of basal and stimulated activity of P-gp with compounds.
This includes comparison of basal and stimulated activity of P-gp in the following categories.
(A), old P-gp in micelles; (B), old P-gp in nanodiscs (L); (C), old P-gp in nanodiscs (S); (D),
optimized P-gp in micelles; (E), optimized P-gp in nanodiscs (L); (F), optimized P-gp in
nanodiscs (S).
3.16 Activity comparison of MSP1E3D1 (L) and MSP1D1 (S) nanodiscs
Due to potential partition of compounds in nanodisc lipids, it seemed important to
compare P-gp nanodiscs encircled with larger versus smaller MSPs, which corresponds to more
and less lipids residing in the nanodiscs. As shown in Figure 42, the slope was ranging from
0.73 to 0.98, indicating a great correlation between large and small nanodiscs of P-gp in response
to our compounds. It also suggested that there was likely no significant partitioning of
compounds in nanodisc lipids, which would otherwise result in different responses between large
and small nanodiscs and cause ineffectiveness of compounds to some extent. The observation
that the R2 values were close to 1 indicated that the data were tightly distributed and the
correlation between large and small nanodiscs was precise. In addition, the average slope value
(0.83, in Table 15) was almost the same as the % positive correlation (84.8%, in Table 15),
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indicating that large and small nanodiscs not only had the same prediction of inhibition or
stimulation but also the level of each of them.

A

Slope: 0.98
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R : 0.89

B

Basal Optimized P-gp
Nanodiscs (S)

Basal Activity of Optimized P-gp Nanodiscs: (L) vs (S)

Basal Optimized P-gp Nanodiscs (L)
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C

Slope: 0.75
2

R : 0.83

D

Stimulated Optimized P-gp
Nanodiscs (S)

Stimulated Activity of Optimized P-gp Nanodiscs: (L) vs (S)

Stimulated Optimized P-gp Nanodiscs (L)

Figure 42 Activity comparison of basal and stimulated activity of P-gp with compounds.
This includes comparison of basal and stimulated activity of P-gp in the following categories.
(A), old P-gp in micelles; (B), old P-gp in nanodiscs (L); (C), old P-gp in nanodiscs (S); (D),
optimized P-gp in micelles; (E), optimized P-gp in nanodiscs (L); (F), optimized P-gp in
nanodiscs (S).
3.17 Summary of activity comparisons
The activity comparisons between old and optimized P-gp, P-gp in micelles and
nanodiscs, basal and stimulated activity of P-gp, and large and small MSP nanodiscs are

120

summarized in Table 15. Slope values from old vs optimized (Figure 39) and large vs small
MSP nanodiscs (Figure 42) comparisons were close to 1 and the percentage of positive
correlation were also close to 1, indicating that protein types (old/optimized) or MSP types in
nanodiscs (large/small) did not affect the results of the compound screening. However, P-gp in
micelles was significantly different from the one in nanodiscs (Figure 40), and the basal and
stimulated activities were not well correlated either (Figure 41), indicating that protein
environments (detergent micelles/lipid nanodiscs) and the presence or absence of transport
substrate drastically affected the screening of compounds. The results indicated that while both
micelles and nanodiscs may be used to assess the effects of to-be-screened compounds, both in
basal and stimulated activity assays, the more native-live environment of P-gp reconstituted
nanodiscs may be a better alternative for future experimentation.
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Table 15 Summary of activity comparisons between old and optimized P-gp, P-gp in micelles
and nanodiscs, basal and stimulated activity of P-gp, and large and small MSP nanodiscs.
They correspond to Figure 39, 40, 41 and 42, respectively. Values of slope and R2 from Figure
39-42 are summarized here. The average slope value for each figure is calculated and shown at
the top of the Slope column (in bold). The percentage of compounds in inhibition/inhibition zone
(% (I/I)), stimulation/stimulation zone (% (S/S)), no effect/no effect zone (% (-/-)), and positive
(+) correlation are calculated and shown in the right four columns.
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CHAPTER 4
DISCUSSION

4.1 Predicted P-gp inhibitors reverse paclitaxel resistance in paclitaxel-resistant prostate
cancer cell line, DU145TXR cells
In order to determine the IC50 values of paclitaxel (PTX) in the presence of our
experimental compounds using the DU145TXR cell line, different concentrations of PTX were
included in resazurin assays [60] with or without 2.5µM compounds (Figure 3 and Table 2). In
this assay, Tariquidar (TQR) was used as a control for our compounds. However, TQR treated
experiment has no PTX IC50 available to show due to not enough data points at lower
concentrations than 1nM. But by looking at its curve itself, it should have a lower PTX IC50
value than our compounds. Therefore, it had a lot of room to improve for our compounds in
order to go to clinical trials in this aspect. Although PTX IC50 values were derived directly from
GraphPad, it should be very straightforward to compare them for different compounds by
looking at their curve locations in the figure. If the curve was more to the left side or more away
from the DMSO treated, it was supposed to have a lower IC50 value. So, a better compound was
able to shift its curve to the left as close as possible to the TQR treated or even more left than the
TQR treated.
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Compounds 117 and 102 from the newer batch was used as examples. Compound 117,
one of the three novel compounds, showed lowest PC50 value (Figure 4 and Table 3), indicating
that in the presence of 500nM paclitaxel it requires the lowest concentration among the four
experimental compounds to inhibit 50% viability of TXR cells. In other words, given the same
concentration of paclitaxel, 117 was the most effective probably due to its highest binding
affinity to P-gp than other compounds. So, when a fixed concentration of 2.5µM experimental
compounds was used for the sensitization assay, in the presence of compound 117 it required
paclitaxel the least concentration to achieve 50% viability inhibition indicated by the paclitaxel
IC50. In other words, at 2.5µM compound 117 inhibited the P-gp the most resulting that it
required the least paclitaxel to inhibit 50% viability (IC50). So, these two experiments looked at
one factor while the other one was fixed. But they overlapped when the two factors were at the
same concentration in these two experiments. Therefore, if one compound can potentiate PTX
cytotoxicity it should also be able to reverse PTX resistance in TXR cells. Not surprisingly,
compound 102 had a lower PC50 value than 108 in the presence of 500nM paclitaxel, which
resulted in a lower paclitaxel IC50 value in the presence of 2.5µM compound 102 than 108.
Furthermore, the highest PC50 and IC50 values were observed for compound 29 in the presence
of 500nM paclitaxel and for paclitaxel in the presence of 2.5µM compound 29, respectively, as
shown in Table 2 and Table 3. Although verapamil had the lowest PC50 value among all
compounds tested, it was not of our interest because it is a transport substrate of P-gp. So far, our
novel compounds were able to reverse paclitaxel resistance in TXR cell line and potentiate
paclitaxel cytotoxicity to TXR cells as well in viability/resazurin assays using a variety of
concentrations of paclitaxel and compounds.
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4.3 Correlation of cellular accumulation of P-gp substrate with cellular viability
Interestingly, the level of the inhibition of the novel compounds that led to the
accumulation of P-gp transport substrate calcein-AM (Figure 5) was the same as those that
affected the viability of TXR cells in the presence of another P-gp substrate paclitaxel as
indicated in Figure 2 and Figure 3 So, it was not very hard to predict that our novel compounds
inhibited P-gp that resulted in the accumulation of paclitaxel which ultimately decreased the
viability of TXR cells. Verapamil was the most effective in potentiating paclitaxel cytotoxicity as
indicated in Figure 3, but it was not ranking the top in promoting the accumulation of calceinAM. One explanation might be verapamil is a substrate of P-gp which might competitively
inhibit the binding of calcein-AM to P-gp while our novel compounds might be inhibiting using
a different mechanism that leads to a stronger inhibition of P-gp. In other words, our compounds
might not be substrates of P-gp but bind to allosteric sites on P-gp or our compounds might bind
to more than one site, one of which might be drug or substrate binding domain though. So, it
would be of interest to figure out mechanisms underlying the inhibition by our novel compounds
in other experiments.
In Eq. 1. used for the calculation of % efflux inhibition in Figure 5B, the slope for each
curve was acquired from the linear regression for each compound instead of the difference
between RFUs divided by time[64]. The reason was that the accumulation curve was not a
straight line thus the slopes could be better represented by values from the linear regressions. It
seemed that the accumulation of calcein-AM tended to slow down with time possibly due to the
increasing concentration of calcein inside cells and the increasing hydrolysis of calcein-AM both
inside and outside of the cells. As calcein was accumulating inside cells, it should have slowed
down toward its saturation. In the meantime, the increasing hydrolysis of calcein itself raised the
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background signal more toward the end than at the beginning of the assay. When the background
noises were subtracted from the fluorescent readings (RFUs) at the beginning and at the end, the
ending RFU will be more dramatically decreased than the beginning RFU, leading to a curved
accumulation toward the X-axis. For this reason, using slopes from curve regressions will be able
to trade off the possible interferences from the two possible resources as discussed above,
especially when the efficiencies of different compounds were compared with each other. This
phenomenon was also observed when a lower concentration of compounds 0.75μM was used as
shown in Figure 6A.
DU145 and TXR cells treated with DMSO were used as controls with 100% and 0%
efflux inhibitions, respectively (Table 5). The RFU slopes of calcein accumulation as shown in
Table 5 for these two are 11132 and 883, which were very similar to the values 10668 and 971
obtained from Table 4, respectively. This indicated that using RFU slopes derived from curve
regressions was able to more accurately and repetitively reflect the true % efflux inhibition
although the linearity of their curves in these two experiments was different due to the two
possible reasons as discussed above. Otherwise, the slopes would be much less repeatable if the
difference between the maximum and minimum RFUs was used for calculations.
4.4 Correlation of migration assay with cellular viability
The ability of cancer cells migrating to other parts within a body is critical in the
metastatic progression of cancers [16]. A migration assay was performed to investigate whether
our newly discovered, experimental compounds also further inhibited migration of TXR cells in
culture in the presence of vinblastine (VIN), a drug that prevents cell migration. Three
compounds, 102, 103 and 117, which were the top hits in the viability assays, also inhibited the
migration of TXR cells in the presence of VIN. The inhibition level in the migration assay also
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correlated with the inhibition in cellular viability assay. This might indicate that the migration
inhibition was caused by the decreased cellular viability by compounds in the presence of VIN.
With VIN or compounds only at any concentration was not able to inhibit the wound
closure by more than 30% as shown in Figure 7A-G, indicating that either VIN or compounds
themselves were not preventing the migration of TXR cells effectively. However, a combination
of VIN and our compounds at either concentration inhibited the wound closure by more than
50%, indicating that our compounds promoted the inhibition of the migration in the presence of
VIN. Among the three compounds here, 102 was the most effective in combination with VIN. At
4µM, 102 was able to inhibit the wound closure by more than 80% while 70% at 2µM.
Compound 103 inhibited the wound closure by about 70% at 2µM or 4µM. Compound 117
inhibited it by 50-60% depending on the concentration of it. Although 117 had the lowest
inhibition among the three compounds at more than 3µM in the presence of VIN, it was able to
inhibit it by more than 20% even in the absence of VIN. So, it seemed VIN was not
synchronizing with 117 as effective as with the other two compounds. Compound 103 was also
inhibiting the migration at 4µM by 30%, but not so much at 2µM. However, if we recall the
toxicity difference of 103 at 10µM and 2.5µM, it was noticed that 103 was toxic at 10µM but not
at 2.5µM. So, it was possible that 103 was also toxic at 4µM, resulting in the inhibition of the
wound closure by itself. In other words, it was possible that it was the toxicity of 103 that caused
the inhibition other than the inhibition from itself. So, it would be interesting to further test its
toxicity at 4µM in future experiments.
4.5 Potential mechanisms underlying inhibition of ATPase activity of purified P-gp by
compounds
101 and 117 might have more than one binding sites on P-gp with one in the drug binding
domain and at least another one at an allosteric site. And the binding of verapamil to P-gp
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changed its conformation that favored the binding of our compounds to the allosteric site to
promote the inhibition over the drug binding domain. But in the absence of verapamil, the drug
binding domain was favored for our compounds. Or, 101 and 117 bind to the allosteric sites of Pgp that stimulated the activity in the absence of verapamil but hindered the conformation that
favors the binding of verapamil[26, 62, 75]. So, verapamil could not stimulate P-gp as much as
in the absence of our compounds, but the stimulated activity by verapamil was still higher than
the basal activity in the presence of our compounds although the former was inhibited while the
latter was stimulated.
Compounds 108, 109 and 112 stimulated both the basal and stimulated activity, so they
were more substrate-like. However, it was also possible they bind to allosteric sites that
stimulated the basal activity and also favored the binding of verapamil that led to a further
stimulation.
In an effort to recover the inhibition of P-gp by compound 45 [39], we optimized the
environments, mixed micelles and nanodiscs. In the optimization of preparation of P-gp in
micelles, the detergents concentration was found to affect the sensitivity of P-gp to compounds.
By lowering the amount of detergents used during wash and elution steps, the inhibition of P-gp
by compound 45 was successfully recovered. The ATPase activity and the protein yield were not
compromised during this process. Other compounds also showed more inhibition of P-gp with
optimized detergent concentration. Although some compounds were able to show more
inhibition, compounds that were more hydrophobic might still partition in detergents and lose
inhibition of P-gp. Nanodisc technology then provides a solution to many of these problems and
may offer advantages over micelles in terms of activity, stability and size [56]. In our test, P-gp
in nanodiscs were more active in the absence or presence of verapamil and more stable. P-gp in
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nanodiscs was significantly different from the one in micelles in the ATPase activity assays in
the presence of compounds. Due to the fact that the activity and stability of P-gp dramatically
affect the ATPase activity inhibition assay, it is better to use nanodiscs over micelles.
Furthermore, nanodiscs mimic the native lipid bilayer so they might represent the true inhibition
of P-gp by compounds although some compounds, such as compound 45, did not show inhibition
of P-gp in nanodiscs. The reason might be compound 45 interacted with the lipids used for
nanodiscs assembly that rendered its ineffectiveness. Other lipids might be necessary to try for
this matter.
By comparing the use of two different sizes of MSPs for nanodiscs assembly of P-gp, we
found that there was not much difference between them when used in the activity inhibition
assays. This indicated that P-gp was successfully incorporated into these two different sizes of
nanodiscs and its conformation in these nanodiscs were likely similar in the presence or absence
of compounds. This might also indicate that P-gp was so flexible that it could potentially insert
into different sizes of nanodiscs without affecting its activity.
Two different version of mouse P-gp, old [65] and optimized [66], were used in the
activity inhibition assay. The old P-gp was generated with all cysteines replaced with alanines,
and the drug resistance that it confers to Saccharomyces Cerevisiae, in vivo, was impaired to
some extent. However, the old P-gp was shown to be still catalytically active and can be purified
from Pichia Pastoris yeast in reasonable quantities [65]. The optimized P-gp more resembles the
wild type of P-gp with cysteines replaced by residues that are more like the native ones, and is
fully functional and highly expressed [66]. While the different residues between the two versions
might interact differently with compounds or cause different local conformations that affected
the compound binding, the activity inhibition assay did not show significant difference between
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these two versions. This indicated that both versions of P-gp could be used to test our
compounds and the residue differences did not dramatically affect the conformation of P-gp for
compound binding in the activity assays.
By comparing the basal and verapamil-stimulated activities of P-gp, we found that
verapamil dramatically changed the conformation of P-gp which potentially affected the binding
of compounds. This observation applied to both versions of P-gp, and P-gp in micelles and
nanodiscs.
4.6 Mechanism of action of the 29 variants
The effects of the 29 variants on verapamil-stimulated ATP hydrolysis rates catalyzed by
P-gp (Table 5A and B) were consistent with the effects observed for the compounds in reversing
MDR caused by P-gp (Tables 2 and 4). Group 1 compound 216 and Group 2 compound 286 had
little effect in either the stimulated ATPase or the MDR reversal assays, likely indicating that
these compounds did not strongly interact with P-gp under the conditions tested in these assays.
To assess whether the 29 variants also interacted with the nucleotide binding sites of Pglycoprotein, titration experiments using an electron spin resonance (ESR) active ATP analog,
SL-ATP were performed, where the amount of P-gp bound SL-ANP was determined in the
presence of the 29 variants (Table 5). The results showed that none of the Group 1 variants
significantly affected ATP binding while two of the Group 2 variants reduced ATP binding to
about 1 mol per mol of protein. This again indicated that the selection process through
ChemGen/selective docking was much more predictive as to the effects the potential inhibitors
had on the enzyme.
Among all compounds tested, the strongest reversal of MDR and the strongest stimulator
of both “basal” and “verapamil-stimulated” ATPase activities was variant 238 of the Group 2
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molecules. Compound 238, while strongly reversing MDR, was also the best transport substrate
of all the variants tested, a characteristic that we deem undesirable for any clinically relevant Pgp modulator lead as discussed above. While our curiosity on the mechanism of action of 238 is
piqued by the observation that this compound also inhibited SL-ANP binding to P-gp (Table 5),
we will not likely consider it for further clinical lead development.
Group 2 compound 255 reversed MDR and moderately accelerated verapamil-stimulated
ATPase rates, an effect that may be related to its role as a transport substrate of P-gp. Compound
280 affected MDR, ATP hydrolysis as well as SL-ANP binding, but was not strong enough in
any of these assays to warrant further study. Finally, Group 2 compound 278 affected MDR
relatively weakly, but did inhibit both ATPase hydrolysis and SL-ANP binding to P-gp and
therefore may warrant further study. Of the 10 new variants of the P-glycoprotein inhibitor
compound 29 that were experimentally tested, compounds 227, 278, 541 and 551 inhibited
verapamil-stimulated ATPase activity of the mouse cysteine-less P-gp similarly to that observed
with the parental compound 29. However, our results using normal human P-gp reconstituted in
a more native-like environment like nanodiscs indicated that relying on ATP hydrolysis assays,
especially when not the same isoform of the enzyme was used and when the enzymes were in
different environments (mixed micelles vs. nanodiscs), interpretations of results may not be as
clear cut as often assumed.
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CHAPTER 5
MATERIALS AND METHODS

Cancer cell lines
Human prostate cancer cell line DU145 [76] and its multidrug resistant subline
DU145TXR were generous gifts from Dr. Evan Keller from University of Michigan [40]. Both
cell lines were maintained in complete media RPMI-1640 with L-glutamine supplemented with
10% fetal bovine serum (FBS, BioWest, Logan, UT), 100 U/mL penicillin and 100 µg/mL
streptomycin at 37°C and 5% CO2. 10 nM paclitaxel (Acros Organics, NJ) was added to the
above media to maintain the positive selection pressure in DU145TXR cell culture.
Western Blotting
The expression level of P-gp in DU145TXR cells after treatment with experimental
compounds was assessed by western blotting. Five million cells were lysed with 500 µL of SDS
containing solution (125 mM Tris, pH 6.8, 20% glycerol (v/v), 4% SDS (w/v), 2% betamercaptoethanol (v/v) with 5 µL of protease inhibitor (P8340, Sigma). The cell lysates were then
filtered through a spin column (QIAprep, Qiagen, CA) at 5,000 rpm at room temperature for 10
min. The filtrates were run on SDS-PAGE and then transferred to a PVDF membrane for 120
min at 110 volts at room temperature. The transferred gel was stained with Coomassie blue to
ensure the transfer efficiency. Another SDS-PAGE gel was run in parallel but not transferred for
comparison. The PVDF membrane was blocked overnight at 4°C in freshly prepared TBS-T
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buffer (12 mM Tris, pH 7.5, 0.5 M NaCl, 0.05% Tween-20) supplemented with 4% (w/v)
powder milk. The membrane was washed three times for 5 min each time with TBS-T buffer at
room temperature before it was incubated with the primary P-gp mouse monoclonal antibody
C219 (Enzo Life Sciences, NY) in 1:500 dilution for 1-2 hours at room temperature on a rocking
platform. The membrane was washed three times with TBS-T buffer, and then the secondary
antibody goat anti-mouse SC-2005 (Santa Cruz Biotechnology, CA) was added and incubated
for 1 hour at room temperature. The membrane was washed with TBS-T and developed with the
enhanced chemiluminescence detection kit (ECL, Thermo Scientific, IL).
Resazurin Cell Viability assay
Resazurin has been widely used in the measurement of cell viability [42, 64]. The
rationale is that resazurin is reduced to resorufin by aerobic respiration of viable cells and results
in a color change from blue to strongly fluorescent with an excitation at 530 nm and an emission
at 590 nm. The fluorescent intensity of the resulting resorufin represented the number of viable
cells [77]. Basically, cells were seeded with 4,000 cells per 150 µL media per well on 96-well
plates. Experimental compounds were added in 24 hours to the cells in plates, and were
incubated for another 48 hours. 6 hours before the completion, 440 µM of resazurin (Acros
Organics, NJ) was added to cells, the fluorescent intensity was measured on a Bio-Tek Synergy 2
multi-mode plate reader (Bio-Tek, Winooski, VT) at 530 nm for excitation and 590 nm for
emission. DMSO was used as the vehicle control, and the chemotherapeutic paclitaxel (Acros
Organics, NJ) was used as the positive control. The cell viability was calculated as the
fluorescent intensity of experimental cells divided by the DMSO treated control cells. All
fluorescent measurements were adjusted to their background fluorescent intensities. The
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background fluorescent intensity was determined by using complete medium in the absence of
cells.
The cell viability was plotted as the mean of at least six replicates per concentration of
compounds or paclitaxel with standard deviation (SD) from at least two independent
experiments. The IC50 or PC50 values were calculated using four-parameter variable slope nonlinear regression following equation: Y=bottom + (top-bottom)/(1 + 10^((logIC50 – X) * Hill
Slope) (GraphPad PrismTM, La Jolla California, USA, Version 6.05).
Scratch Assay
In order to test the migration ability of cells, a scratch was made at the bottom of the
monolayer of cells in 48-well plates [64]. First, DU145TXR cells were seeded with 25,000 cells
per 300 µL complete culture media per well, and let them grow until confluent. A scratch was
made along the diameter of wells at the bottom. Then, media were removed and cells were gently
washed with PBS, pH 7.4 to remove any floating cells along the scratch, while the rest of cell
monolayer was kept intact. Media containing 1% serum was added to wells in the presence of
various concentrations of experimental compounds or DMSO vehicle control with or without 0.1
µM vinblastine. Multiple images along the scratch were taken using BioTek Cytation 5 imaging
multi-mode reader (Bio-Tek, Winooski, VT) right after compounds or chemotherapeutic was
added. In 23 hours, images were taken again in the same position as before to determine change
of the scratch area, which indicated the migration of cells.
Calcein AM assay
As a P-gp substrate, calcein AM (Life Technologies, OR) was used to investigate the
impact of experimental compounds on the transport ability of P-gp. The rational was when P-gp
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in the cellular membrane was inhibited by our test compounds, the pump of Calcein AM out of
cells would be inhibited thus leading to an increased uptake of Calcein AM, which became more
fluorescent inside cells. The fluorescent intensity was directly proportional to the inhibition
efficiency by compounds. This assay was performed as described in [64, 74] with little
modification. Basically, DU145TXR cells were seeded on 96-well plates at 40,000 cells per well
and let them grow until confluent. Media were then removed and experimental compounds at
various concentrations were added with or without calcein AM at 2.5 µM. Images of cells were
taken with an excitation at 485 nm and an emission at 535 nm using BioTek Cytation 5 imaging
multi-mode reader (Bio-Tek, Winooski, VT). DMSO was used as a vehicle control. Previously
identified in-house P-gp inhibitor, SMU 19, which was not a substrate of P-gp, was used as a
negative control. Verapamil, a P-gp substrate [78], was included as a positive control.
Cellular accumulation assay for experimental compounds
Cells used (DU145TXR), cell culturing, cell exposure to compounds, cellular handling
and extractions were performed as described in [64]. LC-MS/MS methods were performed as
described in [79] and as modified in [64]. In order to identify if compounds were inhibitors or
substrates of P-gp, the cellular accumulation of compounds was measured with or without the
treatment of tariquidar (TQR) (MedKoo Biosciences, Chapel Hill, NC), which was identified as
an inhibitor of P-gp [26]. The rational was if a compound was a substrate of P-gp, it would be
trapped inside cells without being pumped out when P-gp was inhibited by TQR. DU145TXR
cells were seeded at 350,000 cells per well on 6-well plates, and were grown for 48 hours. Cells
were changed to fresh media and 5 µM of experimental compounds were added with or without
500 nM tariquidar. Daunorubicin, a substrate of P-gp, was used as a control. In 2.5 hours,
compounds were removed and cells were harvested and aliquoted at 1 million cells/mL in
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Hank’s Balanced Salt Solution (Corning, NY). Samples were subjected to LC-MS/MS analysis
to measure the amount of compounds inside cells. DMSO treated cells were used as blank. For
LC/MS-MS, a standard curve was created first by spiking a gradient amount of compounds to the
blank sample. Samples treated with compounds were added with 0.5 mL 0.15% formic acid and
120 ng/mL n-benzylbenzamide internal standard. Samples were incubated at room temperature
for 10 min and spin down at 16,000 x g. The supernatant was applied to LC/MS-MS using a
Sciex 4000QTRAP mass spectrometer coupled with a Shimadzu Prominence LC
Chromatography system. This work was done in the preclinical pharmacology core laboratory in
University of Texas Southwestern.
Yeast cell culture in Fernbach flasks
P-gp expressing yeast strain Pichia Pastoris GS115 was cultured in Fernbach flasks in
shaker incubators at 28°C, agitated at 275 rpm. First, single clones of cells were isolated on Petri
dishes at 28°C, and then inoculated in 10 mL minimal glycerol media (1.34% YNB, 1% glycerol,
and 0.0002% biotin) for overnight growth. In 24 hours, minimal glycerol media was scaled up to
1 L. In 24 hours, media was changed from minimal glycerol to minimal methanol (1.34% YNB,
0.5% methanol, and 0.0002% biotin) for protein expression by spinning down cells at 4,000 rpm
for 20 min at room temperature and resuspending cells in minimal methanol media. 24 hours
after cells were started to grow in methanol media, they were fed with 100 mL 5% methanol and
the pH of the media was adjusted to 5-6. OD of cell culture was recorded at 600 nm. In another
24 hours, cells were fed the 2nd time the same way as the 1st time, and OD was recorded. 72
hours after cells started to grow in methanol media they were harvested by spinning down cells
at 4,000 rpm at 4°C for 15 min. Cell pellets were resuspended in mPIB buffer (0.33 M sucrose,
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0.3 M Tris, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM EACA, pH 7.4) and stored at 80°C until use.
Yeast cell culture in fermenter
For potential higher P-gp expression in Pichia Pastoris, cells were grown in fermenter
(Microferm Fermentor, New Brunswick, NJ). The procedure was essentially the same as above
until the scale-up from 10 mL overnight culture. 10 mL culture was inoculated in 200 mL
glycerol media for 24 hours and then transferred to 10 L fermenter. OD at 600 nm was recorded
every 4 hours until it reached about 200 where the growth curve plateaued. At this stage, cells
were fed with glycerol media (50%, v/v)) at 18.15 mL/hour/L, dissolved oxygen level was
maintained at 40% (v/v) of the maximum (100%), and pH was maintained at 5 using 14% (v/v)
ammonium hydroxide. The feed was then stopped and glycerol was depleted. Then, the feed
media was changed to methanol (%) at 500 rpm. OD was recorded every 4 hours to monitor the
cell growth, and the feed rate of methanol was adjusted accordingly (1 mL/hour/L for 13 hours, 2
mL/hour/L for 24 hours, 2.4 mL/hour/L for 24 hours, 3 mL/hour/L for 83 hours). The arbitrary
cell mass was calculated as OD reading multiplied by the culture volume. The temperature was
maintained at 28 °C using circulating cool systems (Model 9100, Thermo Scientific & GeneLine
Cooler, Beckman). 5 mL of cell culture from the tank of fermenter was aliquoted every 24 hours
to monitor the P-gp expression level by western blot with anti-P-gp antibody. When the
expression of P-gp reached the highest level and before it dropped, the fermentation was stopped
and cells were harvested as described in yeast cell culture in Fernbach flasks.
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Preparation of microsomal proteins from yeast cells
This procedure was to isolate membrane protein from yeast cells after harvest. Typically,
80 mL of frozen cell pellets were thawed in 37 °C water bath and protease inhibitors (160 µL
pepstatin A, 32 µL Leucine, 16 µL chymostatin, 800 µL of 200 mM PMSF and 800 µL of 200
mM DTT) were added. Then, cells were broken open using 175 mL glass beads in the
BeadBeater (Biospec products, OK). Buffer containing 30% glycerol, 50 mM Tris, 125 mM
NaCl, 10 mM imidazole, pH 8.0 was added to fill to the top of bead beater. Ice with rock salt was
used to avoid overheating of samples during bead beating. A slow spin at 10,000 rpm for 30 min
at 4°C was to remove debris, nuclei, mitochondria and unbroken cells using Beckman Avanti
JXN-26 centrifuge. The supernatants were subjected to a fast spin at 45,000 rpm for 45 min at
4°C using Beckman Optima XPN-80. The resulting pellets where our P-gp was were washed
with microsome wash buffer (20% glycerol, 50 mM Tris, pH 7.4). The washed pellets were
resuspended in Tris buffer (30% glycerol, 50 mM Tris, 125 mM NaCl, 10 mM imidazole, pH
8.0).
P-gp purification
Nickel-NTA columns were used to capture P-gp engineered with His-tag. This procedure
was to isolate P-gp from its native membranes and put it in detergent micelles. First, P-gp
containing microsomes were diluted with Tris buffer (20% glycerol, 50 mM Tris, 50 mM NaCl,
10 mM imidazole, pH 8.0) to 2 mg/mL, and 0.6% DDM (w/v) and 0.01% lyso-PC (w/v) were
added. Then, the sample solution was sonicated in ice-cold water bath (Crest Ultrasonics) for 5
cycles of 5 min, and spin down at 20,000 rpm for 30 min at 4°C using Beckman Optima XPN-80
to remove undissolved microsomal proteins. The supernatants were applied to Ni-NTA gravity
column (QIAGEN), and incubated for 30 min at 4°C. Collect the flow-through at 2 mL/min and
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wash the column with 20 bed volume of wash buffer (20% glycerol, 50 mM Tris, 50 mM NaCl,
20 mM imidazole, pH 7.5) at 1mL/min, followed by 10 bed volume of the second wash buffer
(20% glycerol, 50 mM Tris, 50 mM NaCl, 40 mM imidazole, pH 7.5) at 1 mL/min. Protein were
eluted with buffer (20% glycerol, 50 mM Tris, 50 mM NaCl, 300 mM imidazole, pH 7.5) for 3
bed volumes at 0.5 mL/min. Both buffers for the wash and elution were supplemented with 0.6%
DDM (w/v) and 0.01% lyso-PC (w/v) if not otherwise specified. The eluates were concentrated
to about 150 µL using Amicon 100K centrifugation filters (MilliporeSigma, MA) at 4°C, and
stored at -80°C.
Purification of membrane scaffold protein (MSP)
MSP with His tag was purified using Nickel-NTA columns. Cell pellets from the harvest
of MSP expressing E. coli was resuspended in phosphate buffer (20 mM sodium phosphate, 1
mM PMSF, 1% PMSF, 1% Triton X-100, and 30 mg/mL DNase I), and homogenized at 15,00017,000 psi using a high-pressure homogenizer (Avestin EmulsiFlex-C5, ATA Scientific,
Australia). The sample was then spin down at 16,000 rpm for 30 min at 4°C in Beckman Avanti
JXN-26 centrifuge to remove insoluble cell components. The resulting supernatant was applied
to Ni-NTA column with 5 mL resin, and incubated for 5 min before allowing it to flow through
at 1.5 mL/min. Column was washed with 10 bed volume of Tris buffer I (40 mM Tris, 0.3 M
NaCl, 1% Triton X-100, pH 8.0) at 2 mL/min, 5 bed volume of Tris buffer II (40 mM Tris, 0.3 M
NaCl, 50 mM sodium cholate, 20 mM imidazole, pH 8.0) at 1.5 mL/min, and 7 bed volume of
Tris buffer III (40 mM Tris, 0.3 M NaCl, 50 mM imidazole, pH 8.0) at 1 mL/min. Column was
eluted with 20 mL of Tris buffer IV (40 mM Tris, 0.3 M NaCl, 400 mM imidazole, pH 8.0) at
0.5 mL/min. The eluates were dialyzed in Tris buffer V (20 mM Tris, 100 mM NaCl, pH 8.0) in

140

SnakeSkin Dialysis Tubing (Thermo Scientific, MA) at 4°C. Samples were concentrated to a
final volume of 1 mL with 10,000 MWCO Amicon centrifugal filter units and stored at -80°C.
Reconstitution of P-gp into native-like nanodiscs
Nanodisc assembly of P-gp was achieved by incorporating P-gp into self-assembled lipid
biolayer encircled by purified MSP. Basically, purified P-gp micelles were incubated with a 10x
molar excess of MSP and a 500x molar excess of 40% L-alpha-phosphatidylcholine (PC) from
soybean (Sigma, MA) for 1 hour at room temperature with gentle agitation to facilitate nanodiscs
formation. Biobeads SM-2 (BioRad, CA) that had been presoaked in methanol and washed with
a large amount of water and equilibrated with equilibration buffer (20% glycerol, 50 mM Tris,
pH 7.5, 50 mM NaCl) were added at a ratio of 1.4 g/mL to the assembly mix to remove
detergent. After addition of Biobeads SM-2, the mixture was allowed to incubate for 1.5 hours at
room temperature with shaking to remove detergent from the crude nanodisc sample. The
Biobeads were removed from the crude nanodiscs by piercing the bottom of the centrifuge tube
with a 25-gauge needle and spinning at 1000 x g for 1 min. Empty discs were removed by NiNTA column chromatography at 4°C, utilizing the histidine–tag on P-gp. 6 bed volumes of
column wash buffer (20% glycerol (v/v), 50 mM Tris, pH 7.5, 50 mM NaCl) was then applied.
Purified nanodiscs were eluted from the column by applying 1 bed volume of elution buffer
(20% (v/v) glycerol, 50 mM Tris, pH 7.5 at 4°C, 50 mM NaCl, 300 mM imidazole). Samples
were then analyzed by gradient SDS-PAGE and coupled enzyme assays. Samples were stored at
-80°C.
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Coupled enzymatic assays
The activity of purified P-gp was assessed using a well-established enzymatic assay [39,
50, 51] that coupled the hydrolysis of ATP by P-gp to the oxidization of NADH to NAD+
through the reactions of pyruvate kinase and lactate dehydrogenase [80]. This assay was
performed on 96-well plates at 37°C. To test the effect of experimental compounds on the
activity of P-gp, 25 µM of compounds were added to the reaction mixture including the assay
cocktail (50 mM Tris, pH 7.5, 24 mM MgSO4, 20 mM KCl, 1.94 mM poly(ethylene propylene)
(PEP), 0.058 mg/mL pyruvate kinase, 0.0288 mg/mL lactate dehydrogenase, 1.13 mM NADH,
and 4 mM ATP) and P-gp. The absorbance decrease of NADH at 340 nm was recorded using a
BioTek Eon plate reader. The ATPase activity of P-gp was directly correlated with the rate of
NADH decrease. An extinction coefficient of 6,220 M-1cm-1 at 340 nm was used for calculations
with a path length of 0.6 cm. Once the assay cocktail was added, the reaction was started and the
absorbance reading was recorded. Pre-incubation of assay cocktail for at least 15 min in a 37°C
water bath was required and critical to reflect the ATP hydrolysis rate by P-gp. Typically, 15 to
20 µg of P-gp micelles or 10 to 15 µg of nanodiscs were used in this assay to ensure a descent
signal to noise ratio. Compound 19, previously identified P-gp inhibitor (Brewer, et al, 2014),
was used a positive control for P-gp inhibition. DMSO was used the vehicle control.
ESR Measurements
ESR measurements were as described in Brewer et al, 2014. The amount of proteinbound spin-labeled (SL) adenine nucleotide was determined as the difference between the known
total concentration of SL-ATP (2’,3’-(2,2,5,5,-tetramethyl-3-pyrroline-1-oxyl-3-carboxylic acid
ester) -ATP) [52] added and the free spin-labeled nucleotide (SL-ANP) observed in the
experiment. Hyperbolic curve fitting of the results was performed using GraphPad Prism 7 to
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determine maximum binding and apparent affinity for the spin-labeled nucleotide. The equation
used for the fitting the curves was y=P1*x/(P2+x), where P1 corresponds to the maximum
binding of SL-ANP (moles of SL-ANP bound per mole P-gp), and P2 equals the apparent
dissociation constant for SL-ANP. To quantify the amount of free SL-ANP, standard curves
were established where the signal amplitude of the high field signal of the ESR spectra of free
SL-ANP in the absence of protein was correlated to the concentration of SL-ANP added. All
ESR measurements were performed using a Bruker EMX 6/1 ESR spectrophotometer operating
in X-band mode and equipped with a high sensitivity cavity. Spectra were acquired at a
microwave frequency of 9.33GHz, microwave power of 12.63 mW, 100 kHz modulation
frequency and a resolution of 1024 points. The centerfield of the scan was at 3,325 G and an area
of 100 G was scanned. The peak to peak modulation amplitude was 1G and the time constant
was set to 10.240 ms. The conversion time was 163.84 ms, resulting in a total time sweep of
167.772 s. The signal gain was adjusted for the SL-ATP concentrations in the different
experiments.
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